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Abstract 
 
The primary objective of this research was to examine diabetes with a focus on the timing 
of its diagnosis, the factors associated with diabetes, risk of mortality and hospitalization 
outcomes, and the diagnosis, treatment and management in Newfoundland and Labrador. 
Administrative data were used to develop definitions of early and late diabetes diagnosis based 
on when various complications and comorbidities developed. This dissertation is comprised of 
three studies. The first study aimed to describe factors associated with diabetes, a late diabetes 
diagnosis, and whether these factors are different for males and females. The second study 
compared risk of mortality and hospitalizations for males and females with and without diabetes 
and those diagnosed early and late with diabetes. The third study aimed to describe how family 
physicians diagnose, treat and manage type 2 diabetes and to identify if there were any 
differences in how male and female family physicians diagnose, treat and manage those with 
type 2 diabetes. 
 The findings indicate that different factors are associated with a diabetes diagnosis and its 
timing in males and females. Females living in a rural area, receiving social assistance, having 
poor self perceived health and considering most days stressful appear to have the greatest risk for 
developing diabetes. Females with lower education levels are less likely to be diagnosed late 
with diabetes compared to females with a higher level of education. Females with diabetes have 
a greater risk of mortality than males with diabetes and cardiovascular disease has a greater 
negative impact on females with diabetes than on males, especially when females are diagnosed 
at a later stage. Finally, the majority of family physicians in this province have patients with 
complications present when diagnosed with diabetes. Even though family physicians have 
positive attitudes toward diabetes management, risk factors for diabetes complications are not 
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monitored optimally. Male and female family physicians were similar in their diagnosis, 
treatment and management practices and in their attitudes toward diabetes. 
In conclusion, certain risk factors appear to impact males and females differently and 
more research is needed on the timing of diagnosis and how males and females develop diabetes. 
Different management strategies could be considered for males and females and those diagnosed 
at different stages with diabetes. Family physicians should monitor risk factors for diabetes 
complications more closely in an attempt to manage progression of the disease.  
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CHAPTER 1 Introduction 
 
1.1 Purpose 
The primary objective of this research was to examine diabetes with a focus on the timing 
of its diagnosis. The factors associated with diabetes, risk of mortality and hospitalization 
outcomes, and the diagnosis, treatment and management in Newfoundland and Labrador was 
also examined.   
 
1.2 Organization of Dissertation 
This dissertation is organized into five chapters. Chapter 1 provides an introduction, 
research objectives and literature review. Due to the breadth and depth associated with diabetes 
epidemiology research, my literature review had to be selective and addresses only areas that are 
closely related to my research objectives. This chapter also presents the rationale for examining 
early and late diagnosis of diabetes. In Chapter 2, the factors associated with a diabetes 
diagnosis, a late diabetes diagnosis, and whether these factors are different for males and females 
in Newfoundland and Labrador are examined. In Chapter 3, sex differences in outcomes for 
individuals with and without diabetes and patients diagnosed early and late with diabetes are 
described. Chapter 4 presents how family physicians diagnose, treat and manage type 2 diabetes. 
Finally, Chapter 5 presents a general discussion of findings presented in the previous chapters, 
recommendations for future research, and concluding statements. 
 
1.3 Diabetes Mellitus 
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia (high blood 
sugar) resulting from impaired insulin secretion, impaired effectiveness of insulin action or both. 
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Basically, diabetes is a condition in which the body does not produce enough insulin or does not 
properly use insulin. The hormone insulin is needed to take glucose from the blood and move it 
into the body’s cells where it is used as energy. There are four main types of diabetes including 
type 1, type 2, gestational diabetes and other specific types 
1, 2
.  
Type 1 diabetes is an autoimmune disorder that occurs when the pancreas produces little 
or no insulin. The beta cells in the pancreas are the insulin-producing cells and in type 1 diabetes 
the beta cells are attacked by the body's defence system and as a result produce little or no 
insulin. The reason why this occurs is not fully understood. This type of diabetes is most 
commonly diagnosed in children and adolescents and accounts for about 5-10% of people with 
diabetes. Due to the beta cell destruction, people with type 1 diabetes need injections of insulin 
every day to control the levels of glucose in their blood
1, 2
. 
Type 2 diabetes is a metabolic disorder that usually begins with insulin resistance, in 
which the pancreas does not produce sufficient insulin or the insulin is not metabolized properly. 
Type 2 diabetes, accounting for approximately 90-95% of diabetes cases, typically develops in 
people over 40 years of age but can also occur in children, particularly in obese adolescents. In 
contrast to type 1 diabetes, people with type 2 diabetes do not necessarily need insulin therapy. 
Blood glucose levels can be controlled with proper diet and exercise; however, insulin may be 
needed to control hyperglycemia if diet and lifestyle interventions are not effective
1, 2
. 
Gestational diabetes mellitus (GDM) is a condition that develops in pregnancy involving 
glucose intolerance in varying degrees of severity. GDM carries risks to both mother and infant. 
Women who have had GDM are at a higher risk of developing type 2 diabetes later in life 
compared to women who have not had GDM. Also, children born to mothers with GDM may 
have higher birth weights and are more likely to be delivered via caesarean section than babies 
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born to mothers without GDM. These babies are also at a higher risk of having low blood sugar 
levels after birth and high levels of insulin in the blood. They are also more likely to become 
obese and develop glucose intolerance later in life
1, 2
. 
There are other specific types of diabetes which are relatively uncommon and include 
forms resulting from genetic syndromes, defects in beta cell function or insulin action, infections 
and/or drug induction
1, 2
. 
 
1.4 Natural History of Type 2 Diabetes 
The maintenance of normal blood glucose levels involves three main processes, insulin 
secretion, stimulation of glucose uptake, and suppression of hepatic glucose production. The 
hormone insulin is required to move glucose from the blood into the body’s cells to maintain 
normal plasma glucose levels. Under normal conditions, plasma glucose levels are maintained 
within a narrow range. Initially, an increase in plasma glucose concentrations occurs after 
glucose has been ingested. Insulin is then released by the pancreas in response to the increase in 
plasma glucose. Both hyperinsulinemia (increased levels of insulin in the blood) and 
hyperglycemia (increased levels of glucose in the blood) stimulate glucose uptake by splanchnic 
(liver and gut) and peripheral tissues (primarily muscle) and suppress glucose production by the 
liver
3, 4
. 
Type 2 diabetes is characterized by hyperglycemia, insulin resistance, impaired insulin 
secretion and an increase in glucose production by the liver. The natural history of type 2 
diabetes begins with insulin resistance which is the decreased ability of the body to respond to 
the effects of insulin, resulting in hyperglycemia or high blood glucose
5
. As insulin resistance 
progresses, the pancreatic beta cells increase insulin secretion in an attempt to compensate for 
the decreased responsiveness to insulin and maintain normal glucose tolerance. In these early 
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stages elevated insulin levels will be present
6
. This compensation is successful at first and can 
keep plasma glucose levels within a normal range for up to several years
7
. After some time, 
impaired insulin secretion occurs when beta cell functioning decreases and the pancreas is no 
longer able to produce the required amounts of insulin. Beta cell dysfunction is more serious than 
insulin resistance. With beta cell dysfunction, insulin secretion is impaired whereas with insulin 
resistance, insulin may still be produced. Hepatic glucose production also occurs when the beta 
cells produce increased amounts of insulin to compensate for insulin resistance.
 
The increased 
hepatic glucose production is secondary in the sequence of events that lead to type 2 diabetes but 
is thought to be the main cause of fasting hyperglycemia
6, 8
. It is uncertain whether insulin 
resistance or impaired insulin secretion initiates the development of type 2 diabetes; however, 
both defects must be present before an individual progresses to impaired glucose tolerance
3
. 
Essentially, type 2 diabetes involves two main physiological defects, impaired insulin secretion 
and insulin resistance, which together cause the individual to progress from normal glucose 
tolerance to impaired glucose tolerance and then eventually onto type 2 diabetes
4, 6
. 
A long asymptomatic phase and a gradual onset are very common with type 2 diabetes. 
Previous research has shown that hyperglycemia may be present for more than 20 years
9
 and 
type 2 diabetes can be present for up to 12 years before being diagnosed
10, 11
. Long term 
hyperglycemia is associated with a progressive decline in beta cell functioning with a loss of 
about 4% per year. It is estimated that the loss of beta cell function begins about 12 years before 
diagnosis
12
 and at the time of diagnosis, beta cell functioning is reduced to between 50 and 80% 
of normal and continues to decrease with the duration of type 2 diabetes
13, 14
. 
Individuals with type 2 diabetes often develop a number of chronic microvascular and 
macrovascular complications. Common microvascular complications include retinopathy, 
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nephropathy, neuropathy while common macrovascular complications include coronary artery 
disease, cardiovascular disease, peripheral vascular disease, myocardial infarction and stroke. As 
type 2 diabetes can be present for a long time before being diagnosed, patients with diabetes can 
have complications at the time of initial diagnosis. It has been estimated that 2-39% of newly 
diagnosed patients experience retinopathy, 8-18% nephropathy, 5-13% neuropathy and 8% 
cardiovascular disease
15
. 
Hypertension is a common cormorbidity in individuals with diabetes, occurring in 75% 
of type 2 diabetes patients. As a result, hypertension is an important risk factor for mortality and 
cardiovascular events in individuals with diabetes. When present, hypertension accelerates the 
course of microvascular and macrovascular complications. The risk of mortality due to 
cardiovascular events is increased in individuals with diabetes compared to those without 
diabetes and in hypertensive diabetes patients this risk is even higher
16
. 
 
1.5 Diagnostic Criteria 
 
A fasting plasma glucose (FPG) test, casual plasma glucose (PG) test, a 2 hour plasma 
glucose in a 75 gram oral glucose tolerance test (OGTT) or glycated hemoglobin (HbA1C) can 
be used to positively diagnose a person with diabetes. The FPG test is a blood test that is 
performed to measure the level of glucose in the blood plasma after the person has fasted for 8 
hours. The casual PG test is a blood test that is performed at any time of day without regard to 
when the last meal was consumed. The 2hPG in a 75-g OGTT test is performed after a person 
has fasted for 8 hours. Individuals are given a 75-g glucose drink and 2 hours later the glucose 
level is determined. HbA1C refers to glycated hemoglobin. This is measured to determine the 
average plasma glucose concentration over a period of 2-3 months
2
.  
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Table 1.1 shows the plasma glucose levels required for the diagnosis of diabetes, 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). The term ‘prediabetes’ is 
used to describe individuals with plasma glucose levels just below the threshold for diabetes. 
These individuals are classified as having IFG or IGT
1, 2
. IFG is defined as high blood glucose 
levels after a period of fasting while individuals with IGT have high blood glucose levels after 
eating
17
. Clinically, IFG and IGT represent a similar point along the continuum between normal 
glucose tolerance and type 2 diabetes and both can be used to identify those at risk for 
developing type 2 diabetes
18
. While those with IFG or IGT are at risk for developing type 2 
diabetes, not all individuals with elevated plasma glucose levels will go on to develop the 
disease. It is estimated that in about one third of individuals with IGT, blood glucose levels will 
return to normal within a few years
19
. 
The Canadian Diabetes Association 2013 guidelines recommend routine screening for 
type 2 diabetes using an FPG, casual plasma glucose, 2 hour plasma glucose in 75 g OGTT or 
HbA1C test and this should be performed every 3 years in individuals 40 years of age and older 
or those considered to be at high risk
2
. In contrast, in 2012 the Canadian Task Force on 
Preventive Health Care recommends not routinely screening adults at low to moderate risk. It 
recommends routine screening for adults at high risk every 3-5 years and recommends annual 
screening for adults at very high risk
20
. Both the Canadian Diabetes Association clinical practice 
guidelines and the Canadian Task Force on Preventive Health Care recommend a HbA1C value 
of 6.5% or greater as the threshold for diagnosing diabetes. Also, both leave the decision of 
which test to use to diagnose diabetes to the discretion of the physician and suggest that an 
abnormal level may require repeat testing to confirm a diagnosis of diabetes
2, 20
.  
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Table 1.1: Plasma Glucose Levels for Diagnosis of IFG, IGT and Diabetes 
 
 FPG (mmol/L) 2hPG in a 75-g 
OGTT (mmol/L) 
HbA1C (%) 
IFG 6.1-6.9   
IGT  7.8-11.0  
Prediabetes   6.0-6.4 
Diabetes ≥ 7.0 ≥ 11.1 ≥ 6.5 
Source: Canadian Diabetes Association, Clinical Practice Guidelines, 2013 
 
It would not be cost-effective to provide mass screening for diabetes since the prevalence 
of the disease in the general population is low. Individuals at high risk include those with a first-
degree relative with type 2 diabetes and members of certain ethnic groups (Aboriginal, Hispanic, 
African, Asian or South Asian decent). In addition, having a history of prediabetes, gestational 
diabetes or having given birth to a baby that weighted more than 9 pounds are risk factors for 
type 2 diabetes. Being overweight or obese, having high blood pressure, high cholesterol or 
having microvascular and marcrovascular health complications associated with diabetes are also 
risk factors for type 2 diabetes. Having been diagnosed with polycystic ovary syndrome, 
acanthosis nigricans (skin pigmentation disorder), psychiatric disorders (bipolar, depression, 
schizophrenia) and HIV also places an individual at higher risk for developing type 2 diabetes. 
Finally, being prescribed a glucocorticoid medication, atypical antipsychotics and HAART 
(highly active antiretroviral therapy) are risk factors for type 2 diabetes
2
. 
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1.6 Epidemiology of Type 2 Diabetes 
1.6.1 Prevalence 
The prevalence rate measures the proportion of people in a population who have the 
disease at a point in time
21
. The worldwide prevalence of diabetes has risen dramatically over the 
past two decades. According to the most recent global diabetes estimates, the number of people 
aged 20-79 years with diabetes will be 382 million in 2013, 80% of whom will be from low and 
middle-income countries. This number is expected to increase by 55% to 592 million by 2035. In 
terms of gender differences, more men than women have diabetes (198 million and 184 million, 
respectively). However, this difference is expected to increase to 15 million by 2035 with 303 
million men being diagnosed with diabetes compared to 288 million women. With respect to age, 
almost half of those with diabetes are between 40 and 59 years of age and it is expected that this 
age group will continue to have the largest prevalence into 2035
17, 22
. With increasing 
globalization, lifestyles in low- and middle- income countries often include unhealthy diets, 
obesity, inadequate physical activity and unhealthy habits. These unhealthy lifestyles are 
resulting in increasing numbers of non-communicable disease such as diabetes
23, 24
.  
In the United States, the number of people with diabetes has increased from 5.6 million in 
1980 to 20.9 million in 2011, and the age-adjusted prevalence of diabetes has increased from 
2.8% to 6.4%. Between 1980 and 1998, the age-adjusted prevalence of persons with diabetes was 
similar for males and females. However, in 1999, the percentage for males with diabetes began 
to increase faster than the percentage of females with diabetes. By 2011, more males than 
females had diabetes, 6.9% compared to 5.9%, respectively. From 1980 to 2011, the percentage 
of the population with diabetes increased in all age-groups. Those aged 65-74 years had the 
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highest percentage, followed by those aged 75 or older. In 2011, 21.8% of those 65-74 years of 
age had diabetes, which was 13 times higher than those 45 years of age and younger (1.6%)
25
. 
In Canada, the crude prevalence of diagnosed diabetes was 6.8% in 2008/09, which 
represents almost 2.4 million people living with diabetes. The age-standardized prevalence of 
diabetes for individuals aged 1 year and older increased by 70% between 1998/99 and 2008/09. 
The aging Canadian population and the increased survival of individuals with diabetes have 
contributed to the increased prevalence over the last ten years. Prevalence of diabetes increases 
with age and therefore is much lower in children and adolescents compared to adults. Prevalence 
begins to increase sharply after age 40, peaks in the 75-79 year age group and then begins to 
decline. In terms of gender differences, in 2008/09, more males than females had diabetes, 7.2% 
versus 6.4% respectively. Newfoundland and Labrador had the highest age-standardized 
prevalence of diagnosed diabetes in the country at 6.5% in 2008/09. The eastern provinces 
including Newfoundland and Labrador, Nova Scotia, and New Brunswick had a higher 
prevalence of diabetes compared to the western Canadian provinces of Alberta, British 
Columbia, and Saskatchewan
26
. 
 
1.6.2 Incidence 
The incidence rate is the number of new cases of a disease that occur over period of time 
in a population at risk for developing the disease
21
. From 1980 to 2011, the age-adjusted 
incidence increased from 3.5 to 7.6 per 1,000 population in the United States. In 2011, the age-
adjusted incidence of diabetes was similar for males and females (7.7 versus 7.5 per 1,000 
population, respectively). From 1980 to 2011, the incidence of diabetes has increased in all age-
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groups. For adults aged 65–79 years, the incidence of diabetes has significantly increased from 
6.9 per 1,000 population
 
in 1980 to 15.4 in 2011
25
.  
In Canada, the crude incidence rate of diabetes for individuals aged 1 year and older was 
6.3 per 1,000 population in 2008/09. The incidence rate is much lower in children and 
adolescents compared to adults. Incidence rates increase steadily after age 40, peak in the 70-74 
age group and then start to decrease. The crude incidence rate for males was higher than the rate 
for females aged 1 year and older in 2008/09, 6.8 per 1,000 versus 5.7 per 1,000 respectively. 
Between 1998/99 and 2008/09, there was an overall increase in age-standardized incidence rates 
of diabetes. However, only certain age groups contributed to this increase (children 1-19 years of 
age and adults aged 30-49 years). Since 2006/07, incidence rates appear to be decreasing; 
however, additional years of data are required to determine if this is an aberration or a longer 
term trend
26
. 
 
1.6.3 Undiagnosed Type 2 Diabetes 
Worldwide there are an estimated 175 million people who are living with undiagnosed 
diabetes
17, 22
. In Canada, the current prevalence of diabetes is likely a significant underestimation 
mainly due to large numbers of undiagnosed cases of diabetes. Based on data from the 2007-
2009 Canadian Health Measures Survey, 0.9% of the Canadian population aged six years and 
older has undiagnosed diabetes. This represents about 20% of all diabetes cases
26
. 
 
1.7 Prevention of Type 2 Diabetes 
Both the incidence and prevalence of type 2 diabetes are increasing worldwide and those 
diagnosed with type 2 diabetes are also surviving longer. As a result, the risk of progressing onto 
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serious complications is increased. The potential however, does exist to prevent or at least delay 
the onset of type 2 diabetes. Several studies have examined the potential for both lifestyle and 
pharmacologic interventions in adults to prevent and/or delay the onset of diabetes. The Da Qing 
Impaired Glucose Tolerance and Diabetes Study was the first randomized study to show that 
lifestyle interventions could reduce the incidence of diabetes. In this study, individuals with 
impaired glucose tolerance (IGT) were randomized to a control group or one of three treatment 
groups: dietary intervention, an exercise intervention, or a combination of both. The results 
showed a significant decrease in the incidence of diabetes in individuals with IGT. The incidence 
of diabetes at 6 years was 67.7% in the control group, 43.8% in the diet group, 41.1% in the 
exercise group, and 46.0% in the diet-plus-exercise group. The diet, exercise, and diet-plus-
exercise group had a 31%, 46% and 42% reduction in risk of diabetes over 6 years, 
respectively
27
. 
Similar findings have been observed in the Finnish Diabetes Prevention Study. In this 
study, 522 overweight adults with IGT were randomly assigned to a control or lifestyle 
intervention group and were followed for a mean of 3.2 years. The control group was given 
general information about a healthy diet and exercise while the intervention group received 
personalized diet counselling and were encouraged to undertake 30 minutes of aerobic exercise 
and resistance training per day. The incidence of diabetes after 4 years was 11% in the 
intervention group and 23% in the control group. The risk reduction for diabetes was found to be 
58% for the intervention group. The results also suggest that losing as little as 5% of body weight 
can greatly reduce the risk of progressing from IGT to diabetes
28
. 
In another lifestyle intervention trial, 458 Japanese males with IGT were randomly 
assigned to either a standard intervention (control group) or an intensive intervention and 
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followed for 4 years. Subjects in the control and intervention group were told to maintain a BMI 
of less than 24 kg/m
2
 and less than 22 kg/m
2
, respectively, through diet and exercise. The 
intervention group also received detailed instructions on lifestyle every 3-4 months. The results 
showed that the incidence of diabetes was 9.3% in the control group and 3.0% in the intervention 
group. The risk of diabetes was reduced by 67.4% in the intensive treatment group. In addition, 
individuals who lost weight had a reduced risk of developing diabetes and had improved glucose 
tolerance
29
. 
In addition to lifestyle intervention studies, there have been several pharmacological 
intervention studies. The Diabetes Prevention Program compared the effectiveness of lifestyle 
interventions to the effectiveness of a common diabetes medication in 3234 people with IGT. 
Subjects were randomly assigned to a placebo group, Metformin group (850 mg twice daily), or 
an intensive lifestyle modification group. The lifestyle modification group had goals of at least a 
7% weight loss and at least 150 minutes of physical activity per week. After an average follow-
up period of 2.8 years, the incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-
years in the placebo, Metformin, and lifestyle group, respectively. The risk of diabetes was 
reduced by 58% in the lifestyle intervention group, and 31% in the Metformin group, compared 
with the placebo group. These results suggest that while both lifestyle changes and Metformin 
can reduce the incidence of diabetes, lifestyle changes can be more effective than Metformin in 
preventing diabetes
30
. A systematic review and meta-analysis also found that the use of 
Metformin in individuals with prediabetes (IGT or IFG) decreases the likelihood that prediabetes 
will progress to diabetes
31
. 
The Study to Prevent Non Insulin Dependent Diabetes Mellitus (STOP-NIDDM) trial 
evaluated the effect of Acarbose in reducing the risk of type 2 diabetes in individuals with IGT. 
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Participants were randomly assigned to a placebo group or Acarbose group (100mg three times 
daily). After a mean follow-up of 3.3 years, a 25% reduction in the risk of progression to 
diabetes was observed in the Acarbose treated group compared with the placebo group
32
. 
Additionally, the Diabetes Reduction Assessment with Ramipril and Rosiglitazone 
Medication (DREAM) trial randomized 5269 individuals with IGT and/or fasting plasma glucose 
to receive Rosiglitazone (8 mg daily) or placebo. In this trial, the primary outcome was the 
development of diabetes or death and a secondary outcome was regression to normal glycemia. 
At the end of the study, 11.6% of individuals given Rosiglitazone and 26.0% given placebo 
developed the primary composite outcome. Treatment with Rosiglitazone resulted in a 60% in 
reduction in diabetes or death compared to placebo. Also, 50.5% of those receiving 
Rosiglitazone became normal glycemic compared to 30.3% of those in the placebo group
33
. 
Results from randomized controlled trials (RCT) have found that the risk of 
microvascular complications can be reduced with intensive glucose control; however, the effect 
on macrovascular complications have been less clear. The UK Prospective Diabetes Study 
(UKPDS), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release 
Controlled Evaluation (ADVANCE), Action to Control Cardiovascular Risk in Diabetes 
(ACCORD), and Veterans Affairs Diabetes Trial (VADT) are randomized controlled trials that 
have been conducted to compare the effect of intensive glucose control versus standard glucose 
control on microvascular and macrovascular complications in patients with diabetes. These trials 
found that CVD events can be reduced with intensive glucose control; however, no significant 
effect on CVD mortality or all-cause mortality was found
34-38
.
  
Results from the UKPDS have shown that intensive blood glucose control reduces the 
risk of microvascular complications. In this study, 3867 newly diagnosed patients with type 2 
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diabetes were randomly assigned to either an intensive treatment group (with a Sulphonylurea or 
with insulin), or a conventional treatment group with diet. The results showed that the intensive 
treatment group had a 25% reduction in the risk of microvascular complications over a 10-year 
period
34
. 
The UKPDS also examined whether intensive glucose control with Metformin reduces 
the risk of microvascular and macrovascular complications in overweight patients with newly 
diagnosed type 2 diabetes. Patients were randomly assigned to an intensive treatment group (with 
Metformin) or a conventional treatment group. Patients treated with Metformin, compared with 
the conventional treatment group, had a 32% lower risk of developing any diabetes-related 
endpoint (microvascular and macrovascular complications), a 42% lower risk for diabetes-
related mortality, and a 36% lower risk for all-cause mortality
35
. 
The ADVANCE trial randomly assigned 11,140 patients type 2 diabetes to either a 
standard glucose control group or an intensive glucose control group (with Gliclazide, plus other 
drugs as needed, to achieve HbA1C of 6.5% or less). Compared with standard control, intensive 
glucose control significantly reduced the incidence of major microvascular events (nephropathy 
or retinopathy) but not the incidence of macrovascular events (death from cardiovascular causes, 
nonfatal myocardial infarction, or nonfatal stroke)
36
. 
In the VADT trial, 1791 military veterans were randomly assigned to receive either 
intensive or standard glucose control. The median follow up time was 5.6 years. The results 
showed no significant difference between the two groups in the incidence of macrovascular 
events or microvascular complications, with the exception of albuminuria progression
37
. 
The ACCORD trial attempted to determine whether intensive therapy (targeting HbA1C 
below 6.0%) would reduce the rate of macrovascular events (nonfatal myocardial infarction, 
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nonfatal stroke, or death from cardiovascular causes) compared to standard therapy (targeting 
HbA1C levels from 7.0 to 7.9%) in individuals with type 2 diabetes and either cardiovascular 
disease or cardiovascular risk factors. Unfortunately, this trial was terminated early due to the 
higher mortality of individuals in the intensive group compared with the standard therapy 
group
38
. 
The results from the ACCORD trial suggest that intensive glucose control may cause 
adverse outcomes in some patients since the ACCORD trial was stopped early due to higher 
mortality in the intensive glucose control group compared to the standard control group
38
. In 
addition, the ADVANCE, ACCORD, VADT and UKPDS trials showed higher rates of 
hypoglycemic episodes and weight gain in the group that was treated more intensively
34, 36-38
. A 
recent meta-analysis of RCT’s found that intensive glucose lowering treatments did not 
significantly affect all-cause and CVD mortality. The risk of hypoglycemia was more than twice 
as high in the intensive treatment group compared to the standard treatment group and the 
authors concluded that the harm associated with hypoglycemia may offset any potential benefits 
of intense glucose control
39
. Alternatively, the UKPDS 10-year post-trial follow-up found that 
significant reduction in microvascular risk persisted, and significant reductions in myocardial 
infarction and all-cause mortality were seen in the intensive-control group during follow-up. The 
authors used the term ‘legacy effect’ to describe the continued benefit of intensive treatment40. 
Also, when patients were intensively treated with Metformin in the UKPDS, Metformin did not 
induce weight gain and was associated with less episodes of hypoglycaemia than sulphonylurea 
or insulin therapy
35
. Patients in the ADVANCE, VADT and ACCORD trials had diabetes for a 
number of years before entering the trial, whereas patients in the UKPDS where newly 
diagnosed. This could suggest that the same HbA1C target and treatment plan should not be 
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applied to all patients with diabetes. Perhaps the focus should not only be on glucose control but 
on all CVD risk factors. The Canadian Diabetes Association Clinical Practice Guidelines provide 
recommended targets for glycemic control and suggest that treatment strategies should be 
individualized with consideration given to presence of risk factors
2
. Early and aggressive 
treatment has been suggested for patients that are newly diagnosed and do not have a history of 
CVD while less aggressive treatment may be suitable for older patients with a longer duration 
and a history of CVD
41
. 
 
1.8 Research Objectives 
The objectives of this dissertation are: 
1) To use administrative data to develop a case definition of early and late diabetes 
diagnosis based on when comorbidities or complications develop. 
2) To identify factors associated with a diabetes diagnosis and a late diabetes diagnosis and 
to investigate whether these factors are different for males and females. 
3) To examine sex differences in all-cause and cardiovascular mortality and hospitalization 
for individuals with and without diabetes and patients diagnosed with diabetes early and 
late. 
4) To describe how family physicians diagnose, treat and manage type 2 diabetes and to 
identify if there were any differences in how male and female family physicians 
diagnose, treat and manage those with type 2 diabetes. 
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1.9 Rationale for Examining Early and Late Diabetes Diagnosis 
 Worldwide, there are approximately 382 million people with diabetes and it is estimated 
that 592 million will be affected by 2035. Type 2 diabetes is a progressive disorder that often has 
a gradual onset and a long asymptomatic phase. About 175 million people are unaware they have 
the disease
17, 22
. Insulin resistance and beta-cell dysfunction are largely responsible for the 
development of diabetes and its related complications and both are present very early in the 
natural history of diabetes
42
. Hyperglycemia may be present for more than 20 years
9 
and type 2 
diabetes can be present for up to 12 years before being diagnosed
10, 11
. 
Symptoms of diabetes are often not present or may develop slowly and may not be 
noticed for years. Symptoms such as fatigue, frequent urination and excessive thirst are often 
ignored or can often be attributed to less serious conditions. Singh et al.
43 
investigated the nature 
and duration of symptoms at presentation for diabetes patients and found that 40% had 
symptoms for more than 12 months prior to diagnosis. These people either failed to recognise 
these as diabetes symptoms or did not feel they were serious enough to follow up with a 
physician. Jackson et al.
44
 examined the general public’s knowledge of diabetes and found that 
fewer than one in 20 could name thirst and frequent urination as symptoms. However, 
advertising campaigns have been found to raise awareness of the symptoms of diabetes
45
. 
Lack of knowledge of diabetes symptoms can be a factor in the late diagnosis of the 
disease. However, it is not only knowledge of symptoms that can affect the timing of diagnosis. 
It is also important that the public understand that diabetes is a serious condition. Lamont et al.
46
 
examined the perceived seriousness of diabetes and the implications these perceptions may have 
in practice. The perceptions that general practitioners, nurses and patients held were explored 
using interviews and focus groups to determine if type 2 diabetes is perceived to be serious and if 
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this perception influences screening. A difference of opinion was found between health 
professionals and patients regarding the seriousness of diabetes. Three frameworks were found to 
influence perceptions of the seriousness of diabetes, the medical framework, the political 
framework and the personal framework. Within the medical framework, diabetes was perceived 
to be more serious when intense medical intervention was required. The political framework 
viewed seriousness in terms of national priorities, early detection and financial investments. In 
general, diabetes was not thought to be as politically attractive as diseases such as cancer. The 
personal framework suggests that perceptions of seriousness are determined by attitudes, 
knowledge and experiences of diabetes. The authors suggested that the lack of knowledge about 
diabetes and patients’ beliefs that it is not a serious condition may help to explain the lack of 
motivation that some people have to comply with lifestyle interventions recommended to control 
diabetes
46
. 
As type 2 diabetes can be present for a long time before being diagnosed, patients with 
diabetes can have complications at the time of initial diagnosis
15
. On average a person has 
diabetes for about 5 or 6 years before complications develop
47
. As the number of people with 
diabetes increases it is important to study both early and late diabetes diagnosis. Effective and 
active early management is of utmost importance if good control of diabetes is to be reached and 
late complications prevented. Randomized control trials have suggested that diet and exercise 
can prevent or delay the progression from impaired glucose tolerance to diabetes
27, 28
. Intensive 
lifestyle interventions have been found to be more effective than metformin
30
 and intensive 
blood glucose control has been shown to reduce diabetes related microvascular 
complications
34,35
.  
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Since research from randomized control trials has shown that early diagnosis and 
treatment is beneficial, this thesis will examine how to define early and late diabetes diagnosis; 
what factors are associated with diabetes diagnosis and a late diabetes diagnosis and does this 
differ for males and females; mortality and hospitalization outcomes for males and females with 
diabetes and whether these are associated with the time of diagnosis; and, how male and female 
family physicians diagnose, treat and manage type 2 diabetes. 
 
1.9.1 Defining Early and Late Diabetes Diagnosis 
For the purposes of this thesis, individuals with diabetes were classified as being 
diagnosed ‘early’ or ‘late’ depending on when diabetes related comorbidities or complications 
developed. Individuals early on in the disease course would not be expected to have any diabetes 
related comorbidities or complications around the time of their case date. On the contrary, a late 
diagnosed diabetes patient would likely be experiencing conditions related to diabetes around the 
time of diagnosis. Since type 2 diabetes can be present for 9 to 12 years before being diagnosed, 
complications are often present at the time of diagnosis
10
. Insulin resistance and beta-cell 
dysfunction are largely responsible for the development of diabetes and its related complications 
and both are present very early in the natural history of diabetes
42
. The progression of diabetes 
from pre-diabetes to complications is different for each patient. In some individuals 
complications may develop at lower glucose concentrations or during increases in glucose rather 
than after thresholds for a diagnosis are reached and remain consistent
48
. In fact, diabetes may be 
initially detected at the same time diabetes complications are being diagnosed
49
. For instance, the 
UKPDS found that 50% of patients had diabetes related tissue damage at the time of diagnosis
50
. 
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A case definition of ‘early’ and ‘late’ diagnosis of diabetes was developed based on when 
various comorbidities or complications developed. A series of definitions ranging from specific 
to very broad (6 months to 2 years, before/after diagnosis) were developed and sample sizes were 
assessed (Table 1.2). Incident diabetes cases in the Canadian Chronic Disease Surveillance 
System (CCDSS) with a diabetes case date between Jan. 1, 1998 and Dec. 31, 2005 were 
identified and the early and late case definition was applied. Also, incident diabetes cases in the 
CCDSS with diabetes case date between Jan. 1, 1998 and Dec. 31, 2005 and a Canadian 
Community Health Survey (CCHS) interview date within same timeframe were identified and 
the early and late case definition was applied. Since there was little change in the sample 
distribution across definitions, the range of 6 months before and after diagnosis was used to 
define early and late diabetes diagnosis. In addition, an internal medicine physician was 
consulted and agreed that the definition of 6 months before and after diagnosis was reasonable.  
Administrative data were used to identify individuals diagnosed early and late with 
diabetes. The Canadian Chronic Diseases Surveillance System (CCDSS) was used to identify 
records for those with diabetes. These records were linked to the Medical Care Plan (MCP) Fee-
For-Service Physician Claims Database and the Clinical Database Management System (CDMS)  
data. Those data were used to determine when hospital and physician visits for diabetes related 
comorbidities or complications occurred and these were compared to the diabetes case dates. 
Incident diabetes patients without any diabetes related comorbidities or complications within 6 
months before or after the diabetes case date were classified as being early diagnosed while those 
with a late diagnosis were defined as incident diabetes patients with at least one diabetes related 
comorbidity or complication within 6 months before or after diagnosis.  
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Table 1.2: Sample Size Distribution by Definitions of Early and Late Diabetes Diagnosis 
Definitions CCDSS
1
 CCHS
2
 
Early Late Early Late 
Up to the case date 15741 7028 304 123 
At the time of case date 19037 3462 372 55 
6 months before or after case date 17188 5581 328 99 
1 year prior to case date 18289 4480 353 74 
1 year after case date 16800 5969 321 106 
1 year before or after case date 16146 6623 307 120 
2 years prior to case date 17592 5177 342 85 
2 years after case date 15714 7055 306 121 
2 years before or after case date 14701 8068 287 140 
1
 Incident diabetes cases in the CCDSS with a diabetes case date between Jan. 1, 1998 and Dec. 31, 2005. 
2
 Incident diabetes cases in the CCDSS with diabetes case date between Jan. 1, 1998 and Dec. 31, 2005 and a CCHS 
interview date within same timeframe. 
 
The diabetes related conditions that were used to define early and late status are listed in 
Appendix A. In an effort to capture all late diagnosed cases of diabetes, a broad range of 
comorbidities and complications were included in the case definition. The term ‘comorbidity’ is 
used to describe a condition that is present at the time of diagnosis of the index disease (main 
condition being studied). On the other hand, ‘complications’ are conditions occurring after 
diagnosis of the index disease.
51
  
The date an individual is identified as having diabetes in the CCDSS is not the date that 
diabetes developed. Type 2 diabetes can be present for up to 12 years before being diagnosed
10, 11  
and on average an individual has diabetes for about 5 or 6 years before complications develop
47
. 
Using administrative data, it was not possible to identify what is a comorbidity and what is a 
complication of diabetes since it is not possible to determine when diabetes developed, only 
when it was diagnosed. As a result, all possible comorbidities and complications of diabetes were 
included in the definition of early and late diagnosis. 
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1.10 Rationale for Examining Factors Associated with a Diabetes Diagnosis and a Late 
Diabetes Diagnosis for Males and Females 
Overweight and obesity are one of the most important risk factors for type 2 diabetes. In 
2013, 29.4% of the population of Newfoundland and Labrador (NL) self-reported being obese. 
NL has the highest rate of obesity in the country. Overweight and obesity combined affect 69.2% 
of the NL population. In Canada more males self-reported being obese than females, 20.1% 
versus 17.4%, respectively. However, in NL more females than males self-reported being obese, 
30.9% versus 27.9%
52
.  
Overweight and obesity account for a major proportion of diabetes. The median body 
mass index (BMI) for Canadians with diabetes is 29 kg/m
2
 and 75.6% of individuals with 
diabetes are overweight or obese
26
. Hart et al.
53 
examined the relationship between BMI and the 
development of diabetes in middle aged adults. Age-adjusted odds ratios for overweight men 
were 2.73 (95% CI 2.05-3.64) and 7.26 (95% CI 5.26-10.04) for obese men, compared with the 
normal weight group. The age-adjusted odds ratios for women were 2.54 (95% CI 1.95-3.31) in 
the overweight group and 5.82 (95% CI 4.41-7.68) in the obese group, compared to the normal 
weight group. Similarly, Jiang et al.
54
 also investigated the relationship between excess weight 
and diabetes. Compared to the normal weight group, age-adjusted odds ratios for overweight and 
obese men were 1.7 (95% CI 1.3-2.1) and 3.5 (95% CI 2.8-4.4), respectively. For women the 
age-adjusted odds ratios for overweight were 2.0 (95% CI 1.6-2.6) and 6.3 (95% CI 5.0-7.9) for 
obese, compared to the normal weight group. While both Hart et al.
53
 and Jiang et al.
54
 found that 
odds ratios increased with increasing BMI, odds ratios were higher for women than men in the 
Jiang et al.
54 
study and lower in the Hart et al.
53 
study. 
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Physical inactivity is another important risk factor for diabetes since the incidence of 
diabetes decreases with increasing physical activity
55
. In 2013, 52.4% of the NL population 
reported being physically inactive. This was one of the highest rates in the country, second only 
to Nunavut at 52.6%. In NL more females are physically inactive than males, 54.1% versus 
50.5%, respectively. Randomized control trials have shown that physical activity combined with 
dietary changes can reduce the risk of type 2 diabetes in high risk individuals
27-30
. Jeon et al.
56
 
conducted a systematic review to determine the association between physical activity of 
moderate intensity and risk of type 2 diabetes. Compared with sedentary, the risk of diabetes was 
reduced by 31% for moderate physical activity. 
Cigarette smoking also increases the risk of developing diabetes. Foy et al.
57
 investigated 
the association between smoking and incidence of diabetes in US adults using data from the 
Insulin Resistance Atherosclerosis Study. Individuals, free of diabetes at baseline, were classified 
as never, former, and current smokers and followed for 5 years to determine the incidence of 
diabetes. After adjusting for covariates, current smokers had an increased risk of diabetes than 
never smokers (OR=2.66, 95% CI 1.49-4.77). However, former smokers did not have an 
increased risk of diabetes compared to never smokers (OR=1.31, 95% CI 0.82-2.09). In addition, 
Will et al.
58
 conducted a systematic review and meta-analysis of studies exploring the association 
between active smoking and the incidence of type 2 diabetes. The results showed a dose-
response relationship between smoking and diabetes. The association was greater for heavy 
smokers (RR=1.61, 95% CI 1.43-1.80) than light smokers (RR=1.29, 95% CI 1.13-1.48). 
Compared to nonsmokers, the risk of diabetes was 1.44 (95% CI 1.31-1.58) for active smokers, 
which was higher than the risk for former smokers (RR=1.23, 95% CI 1.14-1.33). In 2012, 
19.7% of the NL population reported being current smokers. This was one of the highest rates in 
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the country, with the territories having the highest smoking rates. In NL more 23.1% of males 
are smokers compared to 16.5% of females
59
. 
Factors such as education, income and socioeconomic status have been found to be 
inversely associated with diabetes. Sacerdote et al.
60
 examined the association between education 
level and risk of type 2 diabetes. Compared with individuals with a high education level, those 
with a low education level had a higher risk of diabetes (HR=1.77, 95% CI 1.69-1.85). In a 
Canadian study, Lysy et al.
61
 compared the incidence of diabetes in neighborhood income 
quintiles. The results show a significantly higher incidence of diabetes in lower income groups 
and diabetes incidence decreased with increasing income quintiles. Agardh et al.
62 
conducted a 
systematic review and meta-analysis to investigate the association between incidence of type 2 
diabetes and socio-economic position (measured by education level, occupation, and income). 
They found that the risk of diabetes is increased in low socio-economic position groups 
compared to high socio-economic position groups. 
Identifying risk factors for diabetes is important as individuals at risk can be identified 
and screened. Early detection of diabetes is important since appropriate management strategies 
can be implemented. If diabetes is to be diagnosed as early as possible it is important to study the 
factors associated with a diabetes diagnosis. This chapter will assess the demographic, lifestyle 
and socioeconomic characteristics of individuals diagnosed with diabetes. Since previous 
research has not explored the characteristics of patients diagnosed with diabetes before and after 
complications develop, these factors will also be examined in this chapter. Since diabetes tends 
to affect males more than females
26 
and females with diabetes tend to have poorer outcomes than 
males
63-72
, sex differences will also be examined in this chapter. 
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1.11 Rationale for Examining Mortality and Hospitalization Outcomes for Males and 
Females with Diabetes and Those Diagnosed Early and Late 
Diabetes is a major cause of premature death and individuals with diabetes are almost 
twice as likely to die from any cause compared to those without diabetes
73-75
. In addition, 
individuals with diabetes could have their life expectancy decreased by about 5-10 years 
compared to those without diabetes
76
. 
Declines in mortality rates in individuals with and without diabetes have been observed 
in both Canada and the United States. Lipscombe et al.
77 
reported that between 1995 and 2005 
the adjusted mortality rate decreased by 25% in people with diabetes in Ontario, Canada.
 
Tierney 
et al.
78
 found that the overall mortality rate decreased 35% among those with diabetes between 
1997 and 2002.
 
Thomas et al.
79
 found that mortality rates for those with type 2 diabetes 
decreased by 13.8% between 1970 and 1994. However, this decrease was much lower than the 
decrease observed in individuals without diabetes at 21.4%. Other studies have observed 
declining mortality rates for men only and suggest that mortality rates in women have actually 
increased over time
80, 81
. Gregg et al.
80
 found that for individuals with diabetes, the all-cause 
mortality rate did not change between 1971 to 1986 and 1988 to 2000. When the data was 
analyzed for men and women separately, mortality rates decreased among men with diabetes but 
not among women with diabetes.
 
Gu et al.
81
 also reported sex differences in mortality from all-
causes, heart disease and ischemic heart disease with rates declining for men between 1971 and 
1993 and increasing for women. 
Cardiovascular disease (CVD) is the most common comorbidity associated with 
diabetes, and with 50% of those with diabetes dying of CVD, it is the most common cause of 
death
17
. Acute myocardial infarction (AMI) and stroke are other common comorbidities 
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associated with diabetes. Individuals with diabetes have an increased risk of all-cause mortality 
and morbidity related to CVD, AMI and stroke compared to individuals without diabetes
70-72,82
. 
While studies have consistently found that individuals with diabetes have a higher risk 
of mortality and hospitalizations compared to those without diabetes, results have been 
inconsistent when comparing males and females. Most studies have found that females with 
diabetes have a greater risk of mortality and hospitalizations than males with diabetes
66-69, 71, 72
. 
Two previous meta-analyses found that diabetes is a stronger risk factor for CVD mortality in 
females than in males; however, studies which did not adjust for major CVD risk factors were 
included in these meta-analyses
63, 65
. A meta-analysis conducted by Kanaya et al.
83
, which 
included studies that controlled for CVD risk factors, found that the risk for CHD mortality, 
non-fatal myocardial infarction, and CVD associated with diabetes were not significantly 
different among males and females. Other studies have found that males with diabetes are at a 
higher risk for coronary heart disease
84
 and stroke
85
 than females with diabetes. 
Not only does Newfoundland and Labrador (NL) have the highest age-standardized 
prevalence of diabetes in Canada
26
, this province also has some of the highest age-standardized 
mortality rates and hospitalization rates for CVD, AMI and stroke in the country
86, 87
. As a result, 
this chapter will examine all-cause and cardiovascular mortality and hospitalization outcomes for 
individuals with and without diabetes. Since previous research has not explored mortality and 
morbidity outcomes for patients diagnosed with diabetes before or after complications develop, 
this chapter will also examine all-cause and cardiovascular mortality and hospitalization 
outcomes for patients diagnosed with diabetes early and late. In addition, since previous research 
has been inconsistent when comparing outcomes for males and females with and without 
diabetes, sex differences in outcomes will also be included in this chapter. 
 27 
1.12 Rationale for Examining the Diagnosis, Treatment and Management of Diabetes 
Type 2 diabetes is a progressive disorder, which often has a gradual onset and a long 
asymptomatic phase. As a result, hyperglycemia can be present for many years
9 
and type 2 
diabetes can be present for up to 12 years before being clinically diagnosed
10, 11
. Diabetes is a 
complex condition and the development of diabetes related complications presents an immense 
challenge for family physicians. Primary care providers often consider diabetes as harder to treat 
compared to other conditions like hypertension and angina. Larme et al.
88
 explored the notion 
that attitudes may impede physician adherence to standards of care. Physicians were asked to 
rate the treatment of diabetes in comparison to other conditions. The results show that physicians 
rated diabetes as harder to treat than hypertension and angina.  
 Symptoms of diabetes are variable and are not present for all patients. Some can develop 
slowly and therefore may not be noticed for years. Also, symptoms are often considered 
insignificant or can be attributed to less serious conditions
43, 89
. At the time of diagnosis, many 
patients have experienced symptoms of diabetes for the 12 months prior to being diagnosed
43
. 
The Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes 
(SHIELD) examined prevalence of diabetes symptoms and their association with diabetes 
diagnosis. SHIELD found that 56% of type 2 diabetes patients experienced one or more diabetes 
related symptom in the previous 12 months before their diagnosis. Frequent urination and 
increased fatigue were the most frequently reported symptoms
90
. The general public’s knowledge 
of diabetes symptoms is poor and they are often not aware of common diabetes symptoms such 
as thirst and frequent urination
44
. As a result, it is essential that family physicians identify 
individuals at risk for diabetes and screen for the disease. O’Connor et al.91 found that 39% of 
patients with undiagnosed diabetes had diabetes-related symptoms at the time of diagnosis. In 
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addition, 57% of patients received their diagnosis during planned visits, while 43% received their 
diagnosis visits for acute care.
 
Family physicians have an opportunity to detect undiagnosed type 2 diabetes and 
impaired glucose tolerance (IGT) in patients presenting for routine care. The Diabetes Screening 
in Canada study (DIASCAN) found that 2.2% of patients had undiagnosed diabetes and 3.5% 
had IGT. Early detection of diabetes is important since appropriate management strategies can be 
implemented, especially for patients who have not yet developed complications
92
. Previous 
research has found that primary care provider attitudes about diabetes impact how patients view 
the disease
93
. Physician attitudes toward diabetes management may be more important than 
knowledge of the disease
94
. The reaction and attitude of physicians at the time of diagnosis are 
important factors that influence the perceived seriousness of the disease and the patients’ 
compliance to treatment
95
. Compliance to treatment is essential for patients to prevent or delay 
diabetes complications. Since family physicians are crucial to identifying and caring for 
individuals with diabetes, this chapter aimed to describe how family physicians diagnose, treat 
and manage type 2 diabetes. 
Previous research has found that female physicians are more likely to provide preventive 
services and counselling than male physicians
96, 97
. Berthold et al.
98
 examined the effect 
physician gender on the quality of type 2 diabetes care. The results suggest that female 
physicians may provide better quality of diabetes care than male physicians. Patients of female 
physicians had lower mean fasting plasma glucose concentrations and HbA1C values compared 
to patients of male physicians. The proportion of patients achieving target values of HbA1C was 
also significantly higher in patients of female physicians. Also, mean LDL cholesterol 
concentrations were lower in the patients of female physicians and the proportion of patients 
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achieving LDL cholesterol target values was higher in patients of female physicians compared to 
patients of male physicians. Similarly, mean systolic and diastolic blood pressure values were 
lower in patients treated by female physicians and the proportion of patients achieving target 
blood pressure values were significantly higher in patients of female physicians compared to 
patients treated by male physicians
98
. 
Kim et al.
99
 also examined the association between physician gender and quality of care. 
They concluded that patients of female physicians received similar quality of care compared to 
patients of male physicians. However, patients of female physicians were slightly more likely to 
have their lipid and HbA1C levels measured over 12 months and were more likely to have lower 
LDL levels than patients of male physicians. A secondary objective of this chapter is to 
determine if there were any differences in how male and female family physicians diagnose, treat 
and manage those with type 2 diabetes. 
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2.1 Abstract 
Objectives: To examine the factors associated with diabetes, a late diabetes diagnosis, and 
whether these factors are different for males and females.  
 
Methods: Cross-sectional study including 7,101 individuals aged ≥25 years in Newfoundland 
and Labrador, Canada (466 with diabetes; 332 diagnosed late). Logistic regression analysis was 
used to determine the factors associated with a diabetes diagnosis and late diabetes diagnosis. 
 
Results: For males, overweight/obesity (OR=1.35, 95% CI 1.06-1.72) was positively associated 
with diabetes while being a regular/occasional drinker (OR=0.53, 95% CI 0.32-0.88) was 
inversely associated with diabetes. Living in a rural area (OR=1.47, 95% CI 1.01-2.15), 
receiving social assistance (OR=2.80, 95% CI 1.52-5.15), having poor self perceived health 
(OR=2.06, 95% CI 1.32-3.21), and considering most days stressful (OR=1.45, 95% CI 1.01-
2.10) were positively associated with diabetes for females. No factors were significantly 
associated with a late diabetes diagnosis for males. Having a low level of formal education 
(OR=0.33, 95% CI 0.11-0.99) was inversely associated with a late diabetes diagnosis for 
females. 
 
Conclusions: The majority of individuals diagnosed with diabetes are diagnosed in the later 
stages of the disease. Certain risk factors appear to impact males and females differently and 
more research is needed on the timing of diagnosis and how males and females develop diabetes. 
These risk factors could be used to diagnose diabetes earlier in both males and females.   
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2.2 Introduction 
 Worldwide, there are approximately 382 million people with diabetes and it is estimated 
that 592 million will be affected by 2035
1, 2
. In Canada, the crude prevalence of diabetes was 
6.8% in 2008/09, with more men having diabetes than women (7.2% versus 6.4%)
3
. 
A challenge with diabetes is diagnosing the disease early in an effort to prevent 
progression to complications. About 175 million people, or half of those who have diabetes, are 
unaware they have the disease
1, 2
. Type 2 diabetes can be present for 9 to 12 years before being 
diagnosed and, as a result, complications are often present at the time of diagnosis
4
. However, 
the potential does exit to prevent or at least delay the onset of type 2 diabetes as several 
randomized control trials have shown that both lifestyle and pharmacologic interventions in 
adults are effective
5-8
. In addition to preventing diabetes, it is also possible to reduce diabetes 
related microvascular complications through intensive blood glucose control
8, 9
. 
In most countries, even though females have lower mortality rates than males, they 
experience poorer health
10, 11
. Diabetes tends to affect males more than females since more males 
are diagnosed with diabetes
3
. In addition, males are diagnosed at lower body mass index (BMI) 
levels than females
12
. Even though more males are living with diabetes, females with diabetes 
have a greater risk of mortality and hospitalization
16-19, 21,22
. 
Various factors are associated with diabetes including older age, overweight or obesity, 
physical inactivity, marital status, smoking, lower education and low income
1, 3
. Early detection 
of diabetes is important since appropriate management strategies can be implemented. As the 
rates of diabetes increase it is important to study the factors associated with late diagnosis of 
diabetes and whether these determinants differ for males and females.  
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2.2.1 Conceptual Framework 
The conceptual framework used in this study was based on that developed by Hertzman, 
Frank and Evans
23
. Using the model developed by Evans and Stoddart
24
, Hertzman, Frank and 
Evans proposed a framework that describes differences in health status between or among 
populations. Their conceptual model is presented as a three dimensional cube with each axis of 
the cube representing dimensions for studying the heterogeneities in health status: i) stages of the 
life cycle; ii) subpopulation partitions; and, iii) sources of heterogeneity. Each of these 
dimensions is further divided into various levels
23
. 
 The stages of the life cycle dimension focuses on age and periods in individuals’ lives 
when they may become vulnerable to disease. The four time periods within this dimension are 
perinatal (preterm to 1 year); misadventure (1-44 years of age); chronic disease (45-74 years of 
age); and, senescense (75+ years of age)
23
. 
 The subpopulation partitions dimension describes characteristics of the population where 
differences in health status may be observed. Populations can be partitioned by socioeconomic 
status, ethnicity/migration, geography, sex, and special populations. Special populations involve 
individuals who share a special characteristic that is related to health status differentials. An 
example of a special population would be vegetarians as they usually have good health
23
. 
 Sources of heterogeneity are mechanisms that operate across different subpopulation 
partitions and stages of the life cycle. The sources of heterogeneity in the framework developed 
by Hertzman, Frank and Evans include reverse causality, differential susceptibility, individual 
lifestyle, physical and social environments, and differential access to/response to health care 
services
23
. 
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2.2.2 Research Objectives 
The objectives of this study are to examine the factors associated with diabetes and 
whether these factors differ for males and females. In addition, the factors associated with a late 
diabetes diagnosis will be explored and whether these factors differ for males and females. 
Our hypothesis is that the factors associated with diabetes will be similar to the factors 
associated with a late diagnosis. Also, the factors associated with diabetes will be different for 
males and females. The factors associated with a late diagnosis will also differ for males and 
females. 
 
2.3 Methods 
2.3.1 Study Design and Data Sources 
  This cross-sectional study utilized administrative and survey data in Newfoundland and 
Labrador (NL), Canada. Databases included were: (i) the Newfoundland and Labrador 
component of the Canadian Chronic Disease Surveillance System (CCDSS), 1998-2005; ii) the 
Canadian Community Health Survey (CCHS), 2000/01, 2003, 2005; (iii) the Clinical Database 
Management System (CDMS), 1997-2006; and, (iv) the Medical Care Plan (MCP) Fee-For-
Service Physician Claims Database, 1997-2006.  
The Canadian Chronic Diseases Surveillance System (CCDSS) is a network of provincial 
and territorial chronic disease surveillance systems that compile administrative health care data 
and send aggregate anonymous data to the Public Health Agency of Canada for national 
analyses. The information from which the CCDSS is composed includes the provincial health 
insurance registry, hospital discharge records, and fee-for-service physician claims. The CCDSS 
uses a nationally validated case definition to identify diabetes cases. The case definition used for 
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the CCDSS has 86% sensitivity and 98% specificity for identifying individuals who had diabetes 
recorded in their primary care charts
25
. To be considered a diabetes case in the CCDSS, an 
individual must have met either of the following criteria: 1) had one hospital discharge with a 
diagnosis of diabetes, or 2) two medical services records with diagnosis of diabetes not more 
than two years apart.  Once included in the CCDSS, cases remain there until a record of their 
death is received or they move out of the province. The CCDSS diabetes case definition excludes 
women with gestational diabetes. Also, it is not possible to distinguish between type 1 and type 2 
diabetes.  
The CCHS is a national cross-sectional survey conducted by Statistics Canada which 
collects information related to health determinants, health status and health system utilization for 
130,000 Canadians. Three cycles of the CCHS (2000/01, 2003, 2005) were combined to increase 
the sample size and to decrease variation in the estimates
26
. 
The CDMS is the provincial hospital separation database that captures demographic, 
clinical and interventional information for patients admitted to all acute health care facilities and 
surgical day care in the province of NL. The MCP system contains information related to 
services provided by fee-for-service physicians under the NL provincial Medical Care Plan.   
 
2.3.2 Diabetes and Early and Late Diagnosis Status 
The dependant variables used in this study were diabetes status and early and late 
diabetes diagnosis status. CCHS respondents aged 25 years and older in Newfoundland and 
Labrador, who consented to share their data, were linked to the CCDSS via MCP number 
(provincial health insurance number) to verify their diabetes status according to the CCDSS case 
definition. All incident diabetes cases, as determined through the CCDSS, comprised the 
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diabetes study sample. A three year clearance period, in which an individual did not have a 
hospital admission or physician visit with a diabetes code, was used to identify incident diabetes 
cases. Previous studies have used between three and five years for clearance periods
25,27-28
, and 
while five years is preferred
28
, three years was used in this study to increase sample size. 
Individuals not diagnosed with diabetes at age 25 years or older, who participated in the CCHS, 
and who consented to share their data were eligible for the non-diabetes group. These cases were 
linked to the CCDSS via MCP number to verify whether or not they had diabetes according to 
the CCDSS case definition. The study population included individuals aged 25 years and older. 
Type 2 diabetes usually develops after the age of 40
1
; however, in an effort to increase the 
sample size, age 25 years and older was used.   
Individuals with diabetes were classified as being diagnosed ‘early’ or ‘late’ depending 
on when diabetes related comorbidities or complications developed. The assumption was made 
that individuals early on in the disease course would not have any diabetes related comorbidities 
or complications around the time of their case date. On the contrary, a late diagnosed diabetes 
patient would likely have conditions related to diabetes around the time they were diagnosed. To 
classify individuals diagnosed early and late, records for those with diabetes were linked to the 
MCP and CDMS data to identify when hospital and physician visits for diabetes related 
comorbidities or complications occurred and these were compared to the diabetes case dates. 
Incident diabetes patients without any diabetes related comorbidities or complications within 6 
months before or after the diabetes case date were classified as early diagnosed while those with 
a late diagnosis were defined as incident diabetes patients with at least one diabetes related 
comorbidities or complication within 6 months before or after diagnosis. The diabetes related 
conditions that were used to define early and late status are listed in Appendix A. This method 
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will identify comorbidities and complications identified through healthcare services covered by 
MCP; however, conditions identified through healthcare services not covered by MCP will not 
be captured. 
 
2.3.3 Covariates 
A number of independent variables were explored in this study and were identified using 
the framework developed by Hertzman, Frank and Evans
23
 as a guide. Using this framework, the 
variables of interest are grouped together under three domains: i) stages of the life cycle, ii) 
subpopulation partitions, and iii) sources of heterogeneity.  
Variables included under the stages of the life cycle domain include age and high blood 
pressure. The subpopulation partition variables included sex, level of education, region of 
residence, and receives social assistance. Low education was defined as less than secondary or 
completed only secondary education while high education was defined as some post-secondary 
education or completed post-secondary education. Urban region of residence was defined in the 
CCHS as an area with a population concentration of 1,000 or more and a population density of 
400 or more per square kilometre based on census counts. 
 
Finally, the sources of heterogeneity variables include self perceived health 
(Excellent/very good/good, fair/poor), body mass index (BMI), leisure time physical activity 
(active/moderately active, inactive), smoking status (former smoker/never smoked, 
occasionally/daily smoker), alcohol consumption (former/non-drinker, regular/occasional 
drinker), marital status, life stress (most days considered stressful/not stressful), sense of 
community belonging, employed in the past 12 months, exposed to second hand smoke at home, 
self perceived unmet health care needs and access to a regular medical doctor. BMI was 
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calculated from self-reported height and weight and classified as normal (18.5 ≤ BMI ≥ 24.9 
kg/m
2) and overweight/obese (BMI ≥ 25 kg/m2). Physical activity level was derived from total 
energy expenditure during leisure time, which uses the frequency and duration of respondents’ 
reported leisure time activities in the previous 3 months. Individuals who were married or 
common law were classified as partnered while individuals who were single, widowed, separated 
or divorced were classified unpartnered.  
 
2.3.4 Data Linkage 
 The linkage of the CCHS to the CCDSS and other administrative databases was 
completed in five steps. Step one involved linking the 2000/01, 2003 and 2005 CCHS share files 
and link files together. The share files contain all variables and all records of CCHS respondents 
who agreed to share their data with Statistic Canada’s partners including the provincial and 
territorial health departments, Health Canada and the Public Health Agency of Canada. Personal 
identifiers were removed from the share files. The link file contains MCP numbers, names and 
dates of birth. Individuals who did not give permission to have their information linked and who 
were under 25 at the time of interview were removed from the share file. The share files and link 
files were linked using the household ID and person ID variables.  
Step two involved linking the CCHS files to the MCP master file using the MCP number. 
This was done to verify the MCP number provided in the link file. For individuals with a missing 
or invalid MCP number in the link file, a unique ID was created using the first four characters of 
surname and given name and the date of birth. This unique ID was then linked to the MCP 
master file. Any record with a missing or invalid MCP number was excluded.  
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Step three involved linking the CCHS files to the CCDSS via MCP number. The CCDSS 
file was used to identify individuals aged 25 years and older who were diagnosed with diabetes. 
Individuals who reported that they had diabetes for more than a year were considered non-
incident cases and excluded.  
In step four, the three CCHS cycles were combined to form the CCHS combined file. An 
individual could have been surveyed in more than one CCHS cycle. When this occurred, answers 
in the most recent cycle were kept and the duplicates were removed. The final CCHS file 
resulted in 7,101 records.  
Finally, the CDMS and MCP data were linked to the final CCHS file via provincial 
health insurance number to identify those diagnosed early and late with diabetes. To determine 
this, physician visits and hospital admission data from the MCP and CDMS data were used to 
identify when hospital and physician visits for diabetes related comorbidities or complications 
occurred and these were compared to the diabetes case dates. A detailed data linkage procedure 
can be found in Appendix B. 
 
2.3.5 Statistical Analysis 
Characteristics of the study population are presented as weighted percentages and 
compared between individuals with and without diabetes and those diagnosed early and late with 
diabetes using chi-square tests and t-tests. To determine the factors associated with a diabetes 
diagnosis and late diabetes diagnosis, logistic regression analysis was used to calculate odds 
ratios (OR). Coefficients of variation and 95% confidence intervals (CI) were estimated using 
Statistics Canada’s Bootvar program. The Bootvar program uses sampling weights to produce 
variance estimates, which is necessary to account for the multistage cluster survey design of the 
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CCHS
29
. Analyses were conducted separately for males and females. All statistical analyses were 
performed using SAS version 9.2 (SAS Institute, Cary, NC) software. 
 
2.3.6 Ethical Considerations 
This study was approved by the Health Research Ethics Authority (HREA) at Memorial 
University of Newfoundland (Appendix C), the research ethics board responsible for reviewing 
research on human subjects in Newfoundland and Labrador. Approval to access data from the 
Newfoundland and Labrador Centre for Health Information was approved by the Centre’s 
Secondary Uses Committee (Appendix D).  
 
2.4 Results 
The study sample consisted of 7,101 individuals, with a mean age of 48.4 years (SD, 14.8 
years). Forty eight percent of the sample were male and 52% were female. Characteristics of the 
study sample by diabetes status and sex are presented in Table 2.1. Overall, 6.7% of the study 
sample had diabetes; 7.6% of males had diabetes compared to 5.9% of females. Males and 
females with diabetes were more likely to be older, live in a rural area and have less education 
than those without diabetes (p<0.01). Females with diabetes were more likely to receive social 
assistance compared to females without diabetes (p<0.01), whereas no difference was found for 
males. Males and females with diabetes were more likely to be overweight/obese and physically 
inactive compared to those without diabetes (p<0.01). Males without diabetes were more likely 
to be smokers compared to males with diabetes (p<0.01), while females had similar smoking 
rates regardless of diabetes status. 
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Table 2.1: Characteristics of the study sample by diabetes status and sex   
 
 
 
 
Males (n=3,144) Females (n=3,957) Total (n=7,101) 
Diabetes 
(n=224) 
No Diabetes 
(n=2,920) 
p 
value
1 
Diabetes 
(n=242) 
No Diabetes 
(n=3,715) 
p 
value
1 
Diabetes 
(n=466) 
No Diabetes 
(n=6,635) 
p 
value
1 
Age (years), mean (SD) 58.9 (12.7) 47.5 (14.3) < 0.01 59.2 (12.1) 47.8 (14.9) < 0.01 59.1 (12.5) 47.6 (14.6) < 0.01 
Has High Blood Pressure, % (n) 43.5% (92) 16.3% (536) < 0.01 46.3% (127) 19.6% (850) < 0.01 44.8% (219) 18.0% (2,808) < 0.01 
Female, % (n) -- -- -- -- -- -- 6.7% (242) 93.3% (3,715) < 0.01 
Low Education, % (n) 54.8% (133) 42.8% (1,314) < 0.01 65.9% (169) 44.8% (1,801) < 0.01 59.9% (302) 43.9% (3,115) < 0.01 
Rural Place of Residence, % (n) 43.3% (93) 41.1% (1,259) < 0.01 44.4% (106) 37.0% (1,459) < 0.01 43.8% (199) 38.9% (2,718) < 0.01 
Receives Social Assistance, % (n) F 6.4% (193) 0.517 16.8% (31)E 8.6% (332) < 0.01 11.1% (43)E 7.6% (525) < 0.01 
Poor/Fair Self Perceived Health,   
% (n) 
29.0% (63)
E 12.0% (398) < 0.01 30.8% (71) 11.0% (445) < 0.01 29.8% (134) 
 
11.5% (843) 
 
< 0.01 
Body Mass Index (BMI), % (n)          
Normal
2 14.8% (44)E 30.0% (882) < 0.01 20.3% (50) 43.5% (176) < 0.01 17.3% (94) 37.0% (2,348) < 0.01 
Overweight
3
/Obese
4 85.2% (178) 70.0% (2,012)  79.7% (176) 56.5% (2,080)  82.7% (354) 63.0% (4,092)  
Physical Activity, % (n)          
Active/Moderately 32.6% (67)E 44.4% (1,225) < 0.01 25.4% (64) 35.8% (1,331) < 0.01 29.2% (131) 39.8% (2,556) < 0.01 
Inactive 67.4% (140) 55.6% (1,583)  74.6% (176) 64.2% (2,352)  70.8% (316) 60.2% (3,935)  
Daily/Occasional Smoker, % (n) 13.3% (36)E 28.5% (867) < 0.01 24.8% (52) 25.6% (970) 0.090 18.5% (88) 27.0% (1,837) < 0.01 
Regular/Occasional Drinker, % (n) 70.3% (157) 85.2% (2,438) < 0.01 52.8% (118) 75.1% (2,658) < 0.01 62.3% (275) 79.9 
% (5,096) 
< 0.01 
Life Stress, % (n)          
   Not Stressful 48.1% (117) 43.6% (1,361) < 0.01 35.4% (104) 38.7% (1,501) < 0.01 42.3% (221) 41.0% (2,862) < 0.01 
   Stressful 51.9% (106) 56.4% (1,554)  64.6% (138) 61.3% (2,213)  57.7% (244) 59.0% (3,767)  
Marital Status, % (n)          
   Partnered 83.5% (170) 81.3% (2,185) < 0.01 64.3% (129) 73.8% (2,474) < 0.01 74.7% (299) 77.4% (4,659) < 0.01 
   Unpartnered 16.5% (54)E 18.7% (733)  35.7% (113) 26.2% (1,241)  25.3% (167) 22.6% (1,974) < 0.01 
Weak Sense of Belonging, % (n) 20.0% (38)E 20.1% (512) 0.785 20.2% (48)E 21.5% (727) 0.006 20.1% (86) 20.9% (1,239) < 0.01 
Unemployed in the last 12 months, 
% (n) 
41.3% (90) 21.6% (673) < 0.01 65.8% (148) 35.8% (1,324) < 0.01 53.0% (238) 29.1% (1,997) < 0.01 
Exposed to Second Hand Smoke at 
Home, % (n)  
12.8% (21)
E 20.5% (389) < 0.01 25.9% (31)E 22.3% (526) < 0.01 18.4% (52)E 21.5% (915) < 0.01 
Self Perceived Unmet Health Care 10.8% (24)
E 10.7% (306) 0.763 11.0% (28)E 13.0% (482) < 0.01 10.9% (52)E 11.9% (788) < 0.01 
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1
Significance level p < 0.05; 
2
BMI = 18.5-24.9; 
3
BMI = 25.0-29.9; 
4
BMI =  30.0; % = weighted percentages; n = unweighted numbers; Data with a coefficient 
of variation (CV) from 16.6% to 33.3% are identified as follows: (E) use with caution; Data with a coefficient of variation (CV) greater than 33.3% were 
suppressed due to extreme sampling variability and are identified as follows: (F) too unreliable to be published. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Needs, % (n)   
Has Regular Medical Doctor, % 
(n) 
94.2% (206) 82.3% (2,248) < 0.01 96.3% (231) 89.8% (3,201) < 0.01 95.2% (437) 86.2% (5,449) < 0.01 
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Characteristics of the diabetes sample by early and late diagnosis status and sex are 
presented in Table 2.2. For individuals with diabetes, 25.8% were diagnosed early and 74.2% 
were diagnosed late. For males, 21.1% were diagnosed with diabetes early and 78.9% were 
diagnosed late, whereas 31.5% of females were diagnosed with diabetes early and 68.5% were 
diagnosed late. Both males and females diagnosed late with diabetes were older than those 
diagnosed early (p<0.01). Males diagnosed late with diabetes were more likely to live in a rural 
area compared to early diagnosed males (p<0.01), whereas no difference was found for females. 
Similarly, males with late diagnoses were more likely to be overweight/obese compared to early 
diagnosed males (p<0.01), while no difference was found for females. On the other hand, 
females with a late diabetes diagnosis were more likely to be physically inactive compared to 
females diagnosed early (p<0.01). Physical activity level for males was similar for those 
diagnosed early and late with diabetes. 
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Table 2.2: Characteristics of the study sample by early and late diabetes diagnosis status and sex   
 
 
 
 
Males (n=224)  Females (n=242)  Total (n=466)  
Early (n=58) Late (n=166) p 
value
1 
Early (n=76) Late (n=176) p 
value
1 
Early (n = 134) Late (n = 332) p 
value
1 
Age (years), mean (SD) 56.1 (11.3) 59.7 (13.0) < 0.01 56.7 (13.2) 60.4 (11.4) < 0.01 56.4 (12.4) 60.0 (12.3) < 0.01 
Female, % (n) -- --  -- --  31.5% (76) 68.5% (166) < 0.01 
Low Education, % (n) 52.6% (33)E 55.4% (100) 0.022 76.8% (56) 60.9% (113) < 0.01 66.1% (89) 57.7% (213) < 0.01 
Rural Place of Residence, % (n) 31.9% (17)E 46.3% (76) < 0.01 45.6% (37)E 43.9% (69) 0.147 39.5% (54)E 45.3% (145) < 0.01 
Receives Social Assistance, % (n) F F  F 15.5% (22)
E  F 10.9% (33)
E 0.249 
Poor/Fair Self Perceived Health,   
% (n) 
22.2% (12)
E 30.8% (51)E < 0.01 26.0% (19)E 33.0% (52)E < 0.01 24.3% (31)E 31.8% (103) < 0.01 
Body Mass Index (BMI), % (n)          
Normal
2 18.8% (12)E 13.7% (32)E < 0.01 21.3% (14)E 19.8% (36)E 0.113 20.2% (26)E 16.3% (68) < 0.01 
Overweight
3
/Obese
4 81.2% (45)E 86.3% (133)  78.7% (57) 80.2% (119)  79.8% (102) 83.7% (252)  
Physical Activity, % (n)          
Active/Moderately 32.7% (20)E 32.6% (47)E 0.912 31.6% (22)E 22.6% (42)E < 0.01 32.1% (42)E 28.1% (89) < 0.01 
Inactive 67.3% (36)E 67.4% (104)  68.4% (54) 77.4% (122)  67.9% (90) 71.9% (226)  
Daily/Occasional Smoker, % (n) 22.9% (15)E 10.7% (21)E < 0.01 32.3% (23)E 21.3% (29)E < 0.01 28.2% (38)E 15.2% (50)E < 0.01 
Regular/Occasional Drinker, % (n) 81.4% (44)E 67.3% (113) < 0.01 57.0% (42)E 50.9% (76) < 0.01 67.9% (86) 60.4% (189) < 0.01 
Life Stress, % (n)          
   Not Stressful 40.6% (29)E 50.1% (88) < 0.01 31.7% (28)E 37.1% (76) < 0.01 35.7% (57) 44.7% (164) < 0.01 
   Stressful 59.4% (29)E 49.9% (77)  68.3% (48)
E 62.9% (90)  64.3% (77) 55.3% (167)  
Marital Status, % (n)          
   Partnered 88.1% (43) 82.2% (127) < 0.01 67.5% (47)E 62.7% (82) < 0.01 76.7% (90) 74.0% (209) < 0.01 
   Unpartnered 11.9% (15)E 17.8% (39)E  32.5% (29)
E 37.3% (84)  23.3% (44)
E 26.0% (123)  
Weak Sense of Belonging, % (n) F F  23.9% (18)
E 18.5% (30)E  19.7% (27)
E 20.3% (59) 0.439 
Unemployed in the last 12 months, 
% (n) 
36.4% (20)
E 42.8% (70) < 0.01 63.0% (44)E 67.1% (104) < 0.01 51.5% (64) 53.6% (174) 0.018 
Exposed to Second Hand Smoke at 
Home, % (n)  
F 10.5% (15)E  25.6% (13)
E 26.0% (18)E 0.787 24.1% (19)E 
 
16.5% (33)
E 
 
< 0.01 
Self Perceived Unmet Health Care 
Needs, % (n) 
F 9.5% (15)E  14.4% (11)
E 9.5% (17)E < 0.01 15.1% (20)E 
 
9.5% (32)
E 
 
< 0.01 
Has Regular Medical Doctor, % (n) 96.1% (54) 93.7% (152) < 0.01 98.4% (73) 95.4% (158) < 0.01 97.4% (127) 94.4% (310) < 0.01 
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1
Significance level p < 0.05; 
2
BMI = 18.5-24.9; 
3
BMI = 25.0-29.9; 
4
BMI =  30.0; % = weighted percentages; n = unweighted numbers; Data with a coefficient 
of variation (CV) from 16.6% to 33.3% are identified as follows: (E) use with caution; Data with a coefficient of variation (CV) greater than 33.3% were 
suppressed due to extreme sampling variability and are identified as follows: (F) too unreliable to be published. 
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Adjusted odds ratios (OR) and 95% confidence intervals (CI) for factors associated 
with diabetes are presented in Table 2.3. High blood pressure was positively associated 
with having diabetes for both males (OR=1.81, 95% CI 1.15-2.85) and females (OR=1.58, 
95% CI 1.03-2.42). Being unemployed in the last 12 months and not having a regular 
doctor were inversely associated with diabetes for both males and females. For males only, 
being overweight or obese (OR=1.35, 95% CI 1.06-1.72) was positively associated with 
diabetes while being a regular or occasional drinker (OR=0.53, 95% CI 0.32-0.88) was 
inversely associated with diabetes. In contrast, living in a rural area (OR=1.47, 95% CI 
1.01-2.15), receiving social assistance (OR=2.80, 95% CI 1.52-5.15), having poor self 
perceived health (OR=2.06, 95% CI 1.32-3.21), and considering most days stressful 
(OR=1.45, 95% CI 1.01-2.10) were positively associated with diabetes for females. 
  Adjusted ORs and 95% CIs for factors associated with a late diabetes diagnosis are 
presented in Table 2.4. For males, no factors were significantly associated with an early or 
late diabetes diagnosis. However, for females, having a low education (OR=0.33, 95% CI 
0.11-0.99) was inversely associated with a late diabetes diagnosis. No other factors were 
significantly associated with a late diabetes diagnosis in females.   
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Table 2.3: Adjusted Odds Ratios (OR) and 95% confidence intervals (CI) for factors                
                  associated with diabetes  
 
 Males Females Total 
Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI) 
Age 1.07 (1.04-1.09)** 1.07 (1.05-1.09)** 1.07 (1.05-1.08)** 
Sex    
Male  -- -- 1.00 
Female  -- -- 0.68 (0.51-0.91)* 
High Blood Pressure    
Yes  1.81 (1.15-2.85)** 1.58 (1.03-2.42)* 1.70 (1.24-2.34)** 
No  1.00 1.00 1.00 
Education    
High  1.00 1.00 1.00 
Low  0.99 (0.64-1.55) 1.11 (0.71-1.73) 1.04 (0.78-1.40) 
Region    
Urban  1.00 1.00 1.00 
Rural  0.94 (0.88-1.54) 1.47 (1.01-2.15)* 1.14 (0.86-1.52) 
Social Assistance    
Yes  0.80 (0.27-2.34) 2.80 (1.52-5.15)** 1.93 (1.15-3.23)* 
No  1.00 1.00 1.00 
Self Perceived Health    
Good/Very Good/Excellent 1.00 1.00 1.00 
Poor/Fair  1.68 (0.92-3.07) 2.06 (1.32-3.21)** 1.80 (1.25-2.60)** 
Body Mass Index (BMI)    
    Normal  1.00 1.00 1.00 
Overweight/Obese  1.35 (1.06-1.72)* 1.10 (0.98-1.22) 1.17 (1.07-1.28)** 
Physical Activity    
Active/Moderately Active  1.00 1.00 1.00 
Inactive  1.52 (0.98-2.37) 1.12 (0.71-1.75) 1.32 (0.95-1.81) 
Smoking Status       
Non Smoker  1.00 1.00 1.00 
Daily/Occasional  0.60 (0.33-1.08) 1.12 (0.68-1.86) 0.83 (0.58-1.18) 
Drinking Status    
Former/Non Drinker  1.00 1.00 1.00 
Regular/Occasional 0.53 (0.32-0.88)* 0.71 (0.48-1.06) 0.61 (0.44-0.85)** 
Life Stress    
Not Stressful  1.00 1.00 1.00 
Stressful  1.08 (0.74-1.59) 1.45 (1.01-2.10)* 1.25 (0.96-1.67) 
Marital Status    
Partnered  1.00 1.00 1.00 
Unpartnered  0.89 (0.55-1.44) 0.97 (0.64-1.46) 0.93 (0.68-1.26) 
Sense of Belonging    
Strong  1.00 1.00 1.00 
Weak  1.19 (0.72-1.98) 0.97 (0.62-1.52) 1.09 (0.78-1.52) 
Employed in the last 12 months    
Yes  1.00 1.00 1.00 
No  0.75 (0.64-0.88)** 0.77 (0.68-0.88)** 0.76 (0.68-0.84)** 
Exposed to Second Hand Smoke    
 56 
Yes  1.04 (0.93-1.16) 1.08 (0.99-1.19) 1.06 (0.99-1.14) 
No  1.00  1.00 1.00 
Self Perceived Unmet Health  
Care Needs 
   
Yes  1.09 (0.54-2.21) 0.88 (0.52-1.48) 0.95 (0.61-1.46) 
No  1.00 1.00 1.00 
Has a Regular Medical Doctor    
Yes  1.00 1.00 1.00 
No  0.50 (0.25-0.99)** 0.30 (0.11-0.83)* 0.40 (0.24-0.67)** 
-- Odds Ratios not calculated for these indicators; **p<0.01; *p<0.05 
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Table 2.4: Adjusted Odds Ratios (OR) and 95% confidence intervals (CI) for factors  
                  associated with a late diabetes diagnosis 
 
 Males Females Total 
Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI) 
Age 1.02 (0.98-1.07) 1.04 (0.98-1.09) 1.02 (0.99-1.06) 
Sex    
Male  -- -- 1.00 
Female  -- -- 0.65 (0.37-1.14) 
Education    
High  1.00 1.00 1.00 
Low  0.71 (0.28-1.84) 0.33 (0.11-0.99)*  0.49 (0.25-0.94)* 
Region    
Urban  1.00 1.00 1.00 
Rural  1.84 (0.64-5.28) 1.05 (0.46-2.39)  1.32 (0.70-2.47) 
Self Perceived Health    
Good/Very Good/Excellent  1.00 1.00 1.00 
Poor/Fair  2.33 (0.73-7.46) 1.13 (0.44-2.87)  1.66 (0.87-3.16) 
Body Mass Index (BMI)    
    Normal  1.00 1.00 1.00 
Overweight/Obese  2.14 (0.62-7.35) 0.99 (0.36-2.71)  1.30 (0.59-2.85)  
Physical Activity    
Active/Moderately Active  1.00 1.00 1.00 
Inactive  1.19 (0.47-2.99) 1.38 (0.57-3.34) 1.26 (0.69-2.33) 
Smoking Status       
Non Smoker  1.00 1.00 1.00 
Daily/Occasional  0.46 (0.12-1.70) 0.72 (0.26-1.99)  0.64 (0.29-1.42)  
Drinking Status    
Former/Non Drinker  1.00 1.00 1.00 
Regular/Occasional  0.47 (0.16-1.35) 0.78 (0.32-1.95)  0.68 (0.37-1.24)  
Life Stress    
Not Stressful 1.00 1.00 1.00 
Stressful  0.62 (0.23-1.64) 0.92 (0.37-2.32)  0.79 (0.41-1.52)  
Marital Status    
Partnered  1.00 1.00 1.00 
Unpartnered 1.58 (0.42-6.02) 0.98 (0.38-2.53)  1.10 (0.51-2.35)  
Employed in the last 12 months    
Yes  1.00 1.00 1.00 
No  0.94 (0.55-1.63) 0.92 (0.64-1.34) 0.96 (0.73-1.26) 
Exposed to Second Hand Smoke    
Yes  -- -- 0.99 (0.84-1.16) 
No  -- -- 1.00 
Self Perceived Unmet Health  
Care Needs 
   
Yes  -- -- 0.47 (0.21-1.05) 
No  -- -- 1.00 
Has a Regular Medial Doctor    
Yes -- -- 1.00 
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No (1) -- -- 2.18 (0.36-13.07)  
-- Odds Ratios not calculated for these indicators; **p<0.01; *p<0.05 
 
2.5 Discussion 
This study found that for males and females, high blood pressure was positively 
associated with diabetes. This finding is consistent with Meisinger et al.
30
 who also found 
that hypertension was strongly associated with diabetes in both males and females. This 
study also found males and females who do not have a regular doctor are less likely to be 
diagnosed with diabetes than those who do. This could be due to the fact that those who 
have a doctor have an increased opportunity to discuss symptoms and to be screened for 
diabetes.   
Being overweight or obese was associated with diabetes for males only in this 
study. Similarly, Njolstad et al.
31
 also found that BMI was positively associated with 
diabetes and, after controlling for other factors, BMI was a stronger predictor in men. 
Previous research has found that men are diagnosed at lower BMI levels than females, 
which suggests that males may be more susceptible to diabetes than females
12
. In addition, 
it has been suggested that abdominal fat is associated with higher risk of diabetes and males 
usually carry weight in their abdominal region while females tend to carry weight in their 
hips and thighs
32
.  
For males only, being a regular or occasional drinker was inversely associated with 
diabetes. A U-shaped relationship has been found between diabetes risk and alcohol 
consumption
33, 34
. A meta-analysis conducted in 2005 found that moderate alcohol 
consumption is associated with a 30% reduced risk of type 2 diabetes in males and 
females
33
. The findings of this study are consistent with a recent study by Rasouli et al.
35
 
which found that moderate alcohol consumption is protective for type 2 diabetes in males 
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but not in females. The authors suggest that females could be more sensitive to the negative 
effects of alcohol compared to males or that females are more likely than males to 
underreport their alcohol intake. 
 This study found that living in a rural area was associated with diabetes for females 
only. The prevalence of diabetes is higher for individuals living in rural areas compared to 
urban areas
36, 37
. In general, diabetes prevalence is higher in males than females
3
. Johnson 
et al.
38
 found diabetes prevalence was highest in rural men; however, mortality rates 
declined slightly for rural men and did not change for rural women between 1995 and 
2006. Individuals living in rural areas are also more likely than urban residents to visit an 
emergency room or be admitted to hospital for the management of diabetes
39
. These 
findings highlight the differences in diabetes outcomes for individuals living in rural areas, 
especially females. 
Receiving social assistance was associated with diabetes for females only in this 
study. Lysy et al.
40
 found that diabetes risk is higher for lower income groups compared to 
higher income groups. In addition, risk was higher for lower income females compared to 
males. Dinca-Panaitescu et al.
36
 also found an association between diabetes and income for 
both males and females, and the odds ratios were higher for females.  
Having poor self-perceived health was positively associated with diabetes for 
females only. Unden et al.
41
 also found that females with diabetes reported having a worse 
health situation than males, and were more likely to rate their health as poor compared to 
males. They conclude that diabetes may be experienced differently for males and females. 
In addition, Badawi et al.
42
 also found that females were less likely to rate their health as 
excellent compared with males. They also found that self-rated health was significantly 
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associated with diabetes complications. One explanation for the discrepancy is that men 
and women use different information when making assessments about their health. Women 
have been found to base their health ratings on both serious and mild diseases, while men 
base them on serious illness only
43
. 
Previous research has also found that stress increases the risk of diabetes
44, 45
. The 
present study found that considering most days stressful was positively associated with 
diabetes for females but not for males. In addition, being unemployed in the last 12 months 
was inversely associated with diabetes for both males and females. This is interesting since 
work stress has been found to increase the risk of diabetes for females while the risk in men 
was decreased by high work demands
46
. 
This study found that females with a low education level, defined as less than 
secondary or completed secondary education, were less likely to be diagnosed late with 
diabetes compared to those with a higher level of education. Research investigating the 
association between early and late diabetes diagnosis and educational attainment has not 
been previously explored; however, research has been conducted on education level as a 
risk factor for diabetes. Most research suggests that individuals with a low level of 
education have a higher risk of diabetes and that the association is stronger in females
47-49
. 
However, Chien et al.
50
 found that higher education levels were significantly associated 
with developing pre-diabetes or type 2 diabetes and this finding was significant for females 
only.  
When comparing literature from other conditions, Sobrino-Vegas et al.
51
 found that 
females with a high education level were more likely to have a delayed HIV diagnosis than 
those with a low education level. The opposite was observed in males. The authors 
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suggested that females with low education levels and males believe they are at higher risk 
for HIV as do their health care providers. As a result, they are offered routine HIV testing 
more than females with high education levels. HIV and diabetes are very different 
conditions since HIV is associated with social stigma and discrimination. However, 
previous research has found that patients with low education levels have more consultation 
time spent on physical examination and nutritional counselling compared to higher 
educated patients
52
. In addition, Piette et al.
53
 examined general communication processes 
and diabetes-specific communication. Patients with lower education levels reported better 
general and diabetes-specific communication than patients with higher education levels. 
Health care providers may spend more time counselling patients that they perceive are in 
need of extra attention or explanation. Physicians may pay particular attention to 
individuals with lower education levels in an effort to diagnose diabetes earlier and since 
females visit their doctors more than males
54
, females with lower education levels may be 
diagnosed with diabetes earlier than females with higher education levels or males. 
Another possible explanation is that demands on an individuals’ time may 
negatively affect his/her health. Adults with diabetes who are the primary caregivers for 
children or the elderly may not have time to obtain health care for themselves
55
. Females 
are usually the primary care givers for their families and often have to balance their 
families’ needs with caring for an aging or sick relative and working outside the home. 
When asked the reasons for delaying or going without care, one in five women state that 
lack of time is a barrier
56
. 
The risk factors identified in this study could be used by physicians to diagnose 
diabetes earlier in both males and females. Also, the findings from this study could also be 
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used by policy makers. For males, lifestyle factors appear to be associated with diabetes. 
However, for females, disadvantages such as living in a rural area, receiving social 
assistance, having poor self perceived health and considering most days stressful is 
positively associated with diabetes. This information could be helpful when developing 
policies and strategies.  
 
2.5.1 Limitations 
There are several limitations that need to be addressed. Firstly, this was a cross-
sectional study and therefore not as strong as a cohort or intervention study. Secondly, the 
covariates in this study are based on self-reported responses from the CCHS. Self-reported 
information can be affected by recall bias and social desirability bias. In addition, the 
CCDSS diabetes case definition does not differentiate between type 1 and type 2 diabetes. 
However, since most adults are diagnosed with type 2 diabetes
1
, it is unlikely to have a 
major impact on the results. Furthermore, the CCDSS diabetes case definition uses 
physician claims data. In Newfoundland and Labrador, approximately one-third of the 
province’s physicians are paid on a salary basis and these physicians are not required to 
submit medical claims so information on these visits is not captured. As a result, the sample 
of diabetes cases may be less than the true number of incident cases. In addition, some 
misclassification could have occurred as individuals with diabetes could have been 
classified as not having diabetes because a salaried physician provided most of their care.  
Also, early and late diabetes diagnosis was determined by linking records for those 
with diabetes to the MCP and CDMS data to identify when hospital and physician visits for 
diabetes related comorbidities or complications occurred and these were compared to the 
 63 
diabetes case dates. The range of 6 months before and after diagnosis was used to define 
early and late diabetes diagnosis. Some misclassification could have occurred as 
comorbidities or complications could have developed outside the 6 month range. 
Conditions such as cardiovascular disease, stroke, and coronary artery disease have similar 
risk factors as diabetes and could be diagnosed at the same time or before diabetes is 
diagnosed. Since many definitions of early and late diabetes diagnosis were tested and 
there was little change in the sample distribution across definitions, we feel that the range 
of 6 months before or after diagnosis is a good definition of early and late diabetes 
diagnosis. However, more research into when comorbidities and complications of diabetes 
develop is needed.  
In addition, the definition of early and late depends on conditions identified through 
healthcare services covered by MCP. Conditions identified through healthcare services not 
covered by MCP could not be captured. Optometry services are not covered under MCP, 
therefore retinopathy would not be captured unless it was included in the CDMS data. 
Also, the list of conditions used in the early and late case definition is extensive. Many of 
these conditions could have been due to conditions other than diabetes. For example, it is 
possible that for conditions such as renal disease, amyloidosis, hyperlipidemia, optic nerve 
problems, polyneuropathies, facial nerve disorders, inflammatory polyneuropathy, 
radiculopathy, and a number of others may not be due to complications of diabetes. 
Conditions such as hypertension may also be present prior to the onset of diabetes. For the 
CCHS cohort, hypertension was the condition that defined a late diagnosis in 30.4% of 
cases. Misclassification bias is a possibility and future research should aim to not only test 
different case definitions of early and late diabetes diagnosis but also to include fewer 
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conditions in the definitions. Finally, even though the problem of small sample sizes is 
reduced by combining CCHS cycles, it is not completely eliminated. 
 
2.6 Conclusion 
In conclusion, the results of this study suggest that different factors are associated 
with diabetes for males and females. The majority of individuals diagnosed with diabetes 
are diagnosed in the later stages of the disease. Certain risk factors appear to impact males 
and females differently and more research is needed on the timing of diagnosis and how 
males and females develop diabetes. These risk factors could be used to diagnose diabetes 
earlier in both males and females.    
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3.1 Abstract 
 
Objective: To compare risk of all-cause, cardiovascular disease (CVD), acute myocardial 
infarction (AMI) and stroke mortality and hospitalizations for males and females with and 
without diabetes and those diagnosed early and late with diabetes. 
 
Methods: Population-based retrospective cohort study including 73,783 individuals aged 
≥25 years in Newfoundland and Labrador, Canada (15,152 with diabetes; 9,517 diagnosed 
late).  
 
Results: Males and females with diabetes had an increased risk of all-cause, CVD and AMI 
mortality and CVD hospitalizations compared to individuals without diabetes and the risk 
was stronger in females than in males. For females, risk of all-cause mortality (HR=1.85, 
95% CI 1.74-1.96) and CVD hospitalizations (HR=2.57, 95% CI 2.24-2.94) was 
significantly higher compared to their male counterparts (HR=1.59, 95% CI 1.51-1.69 and 
HR=1.92, 95% CI 1.72-2.14, respectively). Females diagnosed late had an increased risk of 
CVD mortality (HR=6.54, 95% CI 4.80-8.91) and CVD hospitalizations (HR=5.22, 95% 
CI 4.31-6.33) compared to females without diabetes and both were significantly higher 
compared to their male counterparts (HR=3.44, 95% CI 2.47-4.79 and HR=3.33, 95% CI 
2.80-3.95, respectively).  
 
Conclusions: Females with diabetes have a greater risk of mortality than males with 
diabetes. CVD has a greater impact on females with diabetes than males, especially when 
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diagnosed at a later stage. Different management strategies could be considered for males 
and females and those diagnosed early and late with diabetes.  
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 3.2 Introduction 
 Diabetes has become a health problem of increasing significance in the past two 
decades. The number of individuals with diabetes will increase to 592 million by 2035
1,2
. 
In the United States, the number of people with diabetes tripled from 5.6 million in 1980 to 
17.4 million in 2007
3
. In Canada, almost 2.4 million people aged 1 and older were 
diagnosed with diabetes in 2008/09. The age-standardized prevalence of diabetes increased 
by 70% from 3.3% in 1998/99 to 5.6% in 2008/09 while the age-standardized incidence 
rate has been slightly increasing
4
. 
Diagnosing diabetes early is a challenge since many individuals who meet the 
criteria are often asymptomatic. About 175 million people, or half of those who have 
diabetes, are unaware they have the disease
1,2
. Furthermore, type 2 diabetes can be present 
for 9 to 12 years before being diagnosed and, as a result, complications are often present at 
the time of diagnosis
5
. Insulin resistance and beta-cell dysfunction are largely responsible 
for the development of diabetes and its related complications and both are present very 
early in the natural history of diabetes
6
. However, the potential does exist to prevent or at 
least delay the onset of type 2 diabetes as several randomized control trials have shown that 
both lifestyle and pharmacologic interventions in adults are effective
7-10
. In addition to 
preventing diabetes, it is also possible to reduce diabetes related microvascular 
complications through intensive blood glucose control. Results from the United Kingdom 
Prospective Diabetes Study (UKPDS) have shown that intensive blood glucose control 
reduces diabetes related microvascular complications
10,11
. 
Diabetes is a major cause of premature death and is associated with a 2-fold 
increase in mortality
12-14
. Individuals with type 2 diabetes could have their life 
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expectancy decreased by about 5-10 years compared to those without diabetes
15
. 
Cardiovascular disease (CVD) is the most common comorbidity associated with diabetes, 
and with 50% of those with diabetes dying of CVD it is the most common cause of 
death
1
. Acute myocardial infarction (AMI) and stroke are other common comorbidities 
associated with diabetes. Individuals with diabetes have an increased risk of all-cause 
mortality and morbidity related to CVD, AMI and stroke compared to individuals without 
diabetes
16-19
.  
While studies have consistently found that individuals with diabetes have a higher 
risk of mortality and hospitalizations compared to those without diabetes
 12, 17-19
, results 
have been inconsistent when comparing males and females. Most studies have found that 
females with diabetes have a greater risk of mortality and hospitalizations than males 
with diabetes
17, 19-24
. Two previous meta-analyses found that diabetes is a stronger risk 
factor for CVD mortality in females than in males; however, studies which did not adjust 
for major CVD risk factors were included in these meta-analyses
25,26
. A meta-analysis 
conducted by Kanaya et al.
27
, which included studies that controlled for CVD risk factors, 
found that the risk for CHD mortality, non-fatal MI, and CVD associated with diabetes 
were not significantly different among males and females. Also, other studies have found 
that males with diabetes are at a higher risk for CHD
28
 and stroke than females with 
diabetes
28,29
. 
Not only does Newfoundland and Labrador (NL) have the highest age-standardized 
prevalence of diabetes in Canada
4
, the age-standardized mortality and hospitalization rates 
for CVD, AMI and stroke are some of the highest in the country
30-31
. A better 
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understanding of mortality and hospitalizations associated with diabetes in both males and 
females is important to support diabetes prevention and management.  
 
3.2.1 Conceptual Framework 
The conceptual framework used in this study was based on the behavioural model 
of health service utilization
32
. In this model, environmental factors (health care system and 
external environment), population characteristics and health behaviours interact to 
influence health service utilization. Three categories of determinants are used to describe 
population characteristics, 1) predisposing, 2) enabling, and 3) need. Predisposing factors 
are individual characteristics that influence the use of health services and include 
demographic, social structure, health beliefs, genetic factors and psychological 
characteristics. Enabling factors are those that assist or prevent an individual from using 
health services. Resources specific to individuals and their families as well as the attributes 
of the community in which they reside are enabling factors. Examples of enabling factors 
include income, insurance coverage and urban/rural region of residence. Need factors can 
be described as the reason why an individual would seek health care. Specifically, the 
medical reason/condition present or the health status of the individual as they perceive it or 
as evaluated by a health professional. Need factors are often the most important predictor 
of health service utilization
32
. 
The behavioral model of health service utilization has been widely used in research 
related to health service utilization
33-39
.
 
The extensive use of the Andersen model to guide 
research demonstrates the model’s flexibility. Since the model is a framework used to 
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guide analysis, variables to use are not stipulated
40
 allowing researchers to modify the 
model and add variables. 
The behavioral model of health service utilization was revised to provide the 
conceptual framework used to examine outcomes associated with diabetes for males and 
females (Figure 3.1). In this study, the predisposing variables consist of age and sex while 
the enabling factor is urban/rural region of residence. Need factors include the presence of 
diabetes and related co-morbidities while the outcomes of interest are hospital separations 
and mortality. 
   
Predisposing Factors 
      Age 
      Sex 
 
 
 
Enabling Factors 
     Urban/Rural Region of  
     Residence 
 
 
 
Need Factors 
     Diabetes 
     Co-morbidities 
 
Figure 3.1: Revised Behavioral Model of Health Service Utilization to Examine 
Outcomes Associated with Diabetes for Males and Females 
 
 
 
 
 
Outcomes 
        Hospital Separations 
        Mortality 
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3.2.2 Research Objectives 
The objectives of this study are 1) to compare the risk of all-cause, CVD, AMI, and 
stroke mortality and hospitalizations for males and females with and without diabetes, and 
2) to assess and compare the risk of outcomes for males and females that did not have 
complications present at the time of diagnosis (early diagnosis) and for those that had 
complications at the time of diagnosis (late diagnosis). Our hypothesis is that risk of all-
cause, CVD, AMI, and stroke mortality and hospitalizations will be higher for individuals 
with diabetes compared to those without diabetes. Risk of these outcomes will also be 
higher for individuals diagnosed early and late with diabetes compared to those without 
diabetes. In addition, we hypothesize that females will have a higher risk of these outcomes 
than males.  
 
3.3 Methods 
3.3.1 Study Design and Data Sources 
This study was a population based retrospective cohort using administrative 
databases in Newfoundland and Labrador (NL). Databases included were: 1) Canadian 
Chronic Diseases Surveillance System (CCDSS) which uses provincial health insurance 
registries, hospital discharge records, and fee-for-service physician claims to identify 
individuals with diabetes; 2) the Clinical Database Management System (CDMS) which 
contains hospital separation data;  3) the Medical Care Plan (MCP) fee-for-service 
physician claims database which contains billing claims for fee-for-service physicians in 
NL; 4) the Newfoundland and Labrador Centre for Health Information (NLCHI) Mortality 
System, and 5) Statistics Canada Annual Mortality Data Files.  
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 The Canadian Chronic Diseases Surveillance System (CCDSS) is a network of 
provincial and territorial chronic disease surveillance systems that compile administrative 
health care data relating to diabetes and send aggregate anonymous data to the Public 
Health Agency of Canada for national analyses. The information from which the CCDSS is 
composed includes the provincial health insurance registry, hospital discharge records, and 
fee-for-service physician claims. The CCDSS uses a nationally validated case definition to 
identify diabetes cases. The case definition used for the CCDSS has 86% sensitivity and 
98% specificity for identifying individuals who had diabetes recorded in their primary care 
charts
41
. To be considered a diabetes case in the CCDSS, an individual must have met 
either of the following criteria: 1) had one hospital discharge with a diagnosis of diabetes or 
2) two medical services records with diagnosis of diabetes not more than two years apart.  
Once included in the CCDSS, cases remain there until a record of their death is received or 
they move out of the province. The CCDSS diabetes case definition excludes women with 
gestational diabetes and cannot distinguish between type 1 and type 2 diabetes.  
The CDMS is the provincial hospital separation database that captures 
demographic, clinical and interventional information for patients admitted to all acute 
health care facilities and surgical day care in the province of NL. The MCP system contains 
information related to services provided by fee-for-service physicians under the NL 
provincial Medical Care Plan.   
 The NLCHI Mortality System contains data extracted from provincial death 
notifications including demographics, health insurance number and conditions surrounding 
each death. Data are available since 1991. Conditions and/or diseases present at death are 
recorded but there is no indication of which of these leads directly to death (i.e. the 
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underlying cause of death). Diagnoses associated with the death are captured based on the 
International Classification of Disease (ICD), versions nine (1995/96 to 2000/2001) and ten 
(2001/02 to 2007/08).   
 The Statistics Canada Annual Mortality Data Files are a compilation of data from 
provincial and territorial offices of vital statistics that are submitted annually to Statistics 
Canada and contain data on deaths in Canada. Data are available since 1993. Diagnoses 
associated with the death are captured based on the International Classification of Disease 
(ICD), versions nine (1995/96 to 2000/2001) and ten (2001/02 to 2007/08). While data 
contained in the NLCHI Mortality system is more current, Statistics Canada Annual 
Mortality Data Files include the underlying cause of death. 
 
3.3.2 Diabetes and early and late diagnosis status 
 The exposed group included all residents of Newfoundland and Labrador aged 25 years 
and older identified in the CCDSS as having a diabetes diagnosis between April 1, 1998 
and March 31, 2003. The study entry date for the exposed group was the diabetes case date, 
which is defined as the latest date of hospital admission or the later of the two physician 
claims that contribute to the CCDSS case definition. A three year clearance period, in 
which an individual did not have a hospital admission or physician visit with a diabetes 
code, was used to identify incident diabetes cases. Previous studies have used between 
three and five years for clearance periods
41-43
, and while five years is preferred
43
, three 
years was used in this study to increase sample size. 
Individuals with diabetes were classified as being diagnosed ‘early’ or ‘late’ 
depending on when diabetes related comorbidities or complications developed. Individuals 
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early on in the disease course would not be expected to have any diabetes related 
comorbidities or complications around the time of their case date. On the contrary, a late 
diagnosed diabetes patient would likely already have conditions related to diabetes around 
the time of diagnosis. To classify individuals diagnosed early and late, records for those 
with diabetes were linked to the MCP and CDMS data to identify when hospital and 
physician visits for diabetes related comorbidities or complications occurred and these were 
compared to the diabetes case dates. Incident diabetes patients without any diabetes related 
comorbidities or complications within 6 months before or after the diabetes case date were 
classified as early diagnosed while those with a late diagnosis were defined as incident 
diabetes patients with at least one diabetes related comorbidity or complication within 6 
months before or after diagnosis. The diabetes related conditions that were used to define 
early and late status are listed in Appendix A. This method will identify comorbidities and 
complications identified through healthcare services covered by MCP; however, conditions 
identified through healthcare services not covered will not be captured. 
 Residents of Newfoundland and Labrador aged 25 years and older who had at least 
one hospitalization or fee-for-service physician visit between April 1, 1998 and March 31, 
2003 and were not identified in the CCDSS as having diabetes were eligible to be included 
in the unexposed group. Using frequency matching by sex and 5-year age groups, each 
exposed individual was matched to four randomly selected individuals without diabetes.  
The exposed and unexposed groups included individuals aged 25 years and older. 
Type 2 diabetes usually develops after the age of 40
1
; however, in an effort to increase the 
sample size, age 25 years and older was used.   
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3.3.3 Data Linkage 
 The linkage of the CCDSS data to the other databases was completed in seven 
steps. Step one involved identifying the exposed group (diabetes cases). Individuals 
diagnosed with diabetes between April 1, 1998 and Mar. 31, 2003 were identified and 
extracted from the CCDSS. Even though the CCDSS has information from January 1, 1995 
to March 31, 1998, data from this time period was excluded to help ensure only newly 
diagnosed cases of diabetes were included (only individuals diagnosed with diabetes after 
March 31, 1998).  
 In step two, the early and late definitions were applied to determine which 
individuals with diabetes were classified as having an early or late diagnosis. This was 
achieved by linking diabetes cases to the MCP and CDMS data. Diabetes case dates were 
then compared to dates of hospital admissions and physician visits for diabetes related 
complications.   
 In step three, the unexposed group was identified (individuals without diabetes). 
The CCDSS was linked to the MCP and CDMS data to identify individuals aged 25 years 
and older who were not present in the CCDSS. Using frequency matching by sex and 5-
year age groups, each exposed individual was matched to four randomly selected 
individuals without diabetes.  
 Step four involved linking to the MCP and CDMS data to determine if individuals 
with diabetes and those without diabetes were admitted to hospital or had physician visits 
for the outcomes of interest between January 1, 1995 and March 31, 1998.  In step five, the 
file containing the diabetes and non-diabetes cases was linked to the MCP and CDMS to 
identify comorbidities using the Charlson Comorbidity Index (CCI). The CDMS data was 
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also used to identify hospital separations and length of stay for each individual in the study 
sample between April 1, 1998 and March 31, 2008.  
 In step six, the data were linked to NLCHI Mortality System (1998 to 2008) and 
Statistics Canada Annual Mortality Data Files (1998 to 2007) to capture those who had 
died. Finally, the data were linked to the neighbourhood socioeconomic status (SES) 
database to derive an SES score for each individual. This database contains an SES score 
that was developed by Audas, Cirtwill, and O‘Keefe (2007)44. This score is based on social 
and economic variables, including employment, education, and income from the 2001 
census. The SES score ranges from -24.0 to +24.0, with -24.0 representing the poorest and 
+24.0 representing the richest. 
 
3.3.4 Outcomes and Follow-up 
The outcomes of interest were mortality and hospitalizations due to all-causes, 
CVD (ICD-9 390-459; ICD-10-CA I00-I99), AMI (ICD-9 410; ICD-10-CA I21-I22), and 
stroke (ICD-9 430-436; ICD-10-CA I60-I64). The reference group used included 
individuals without diabetes for all analyses. Each outcome was assessed separately. 
Individuals who had a hospital admission or physician visit for CVD between January 1, 
1995 and March 31, 1998 were excluded from the CVD analysis. Similar exclusions were 
made for the AMI and stroke analysis. For hospitalizations and all-cause mortality reported 
in this study, individuals were followed until March 31, 2008 (December 31, 2007 for 
cause specific mortality) or until one of two exit events: death or moved out of province. 
For the hospitalization analysis, hospitalization was also included as an exit event. For 
cause-specific outcomes, all other hospitalizations were censored. For example, for the 
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CVD hospitalization analysis, non-CVD hospitalizations were censored. The exposed and 
unexposed cohorts entered the study between April 1, 1998 and March 31, 2003 and 
followed until March 31, 2008 (December 31, 2007 for cause specific mortality). This 
allowed for a minimum follow-up period of five years, for those entering the study in 2003, 
and a maximum follow-up period of 10 years, for those entering the study in 1998. 
Individuals who died prior to their study entry date were identified by linking to the 
NLCHI Mortality System and the Statistics Canada Annual Mortality Data Files and 
excluded. 
 
3.3.5 Covariates 
 Region of residence, comorbidities and socioeconomic status (SES) were 
considered covariates in the analysis. An urban place of residence was defined as an area 
with 5,000 inhabitants or more while a rural place of residence was defined as an area with 
less than 5,000 inhabitants. This definition was used in an effort to define communities as 
urban and rural so they would match the urban and rural communities in the Canadian 
Community Health Survey (CCHS). Urban region of residence is defined in the CCHS as 
an area with a population concentration of 1,000 or more and a population density of 400 or 
more per square kilometre based on census counts. For this study, population estimates 
were identified for each standard geographical classification (SGC). SGC’s with a 
population greater than or equal to 5,000 was defined as urban and compared to the CCHS 
classification. Similar comparisons were made for rural communities. Approximately 5.5% 
(4,040) of the study subjects did not have information on place of residence. The most 
commonly occurring category was assigned to the missing cases.  
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 Comorbidities at baseline were estimated using the Charlson Comorbidity Index 
(CCI)
45
. The CCI is one of the most frequently used indexes that controls for comorbid 
conditions. Comorbidities were identified through diagnosis codes in the CDMS and MCP 
data and a comorbidity score, representing severity of illness, was assigned to each 
individual. The CCI was initially developed to predict in-hospital and 1-year mortality
43
; 
however, it has since been adapted for use with administrative data using ICD-9 and ICD-
10-CA codes and has been shown to perform well
46, 47
.  
 The neighbourhood SES database was used to derive an SES score for each 
individual. This database contains an SES score for each postal code in NL. This score is 
based on social and economic variables, including employment, education, and income 
from the 2001 census. The SES score ranges from -24.0 to +24.0, with -24.0 representing 
the poorest and +24.0 representing the richest. Approximately 3.2% (2,338) of the study 
subjects did not have information on SES so values were imputed using the median value 
imputation method. SES scores were divided into 5 quintiles with the first quintile 
representing the lowest SES group and the 5
th
 quintile representing the highest SES group. 
 
3.3.6 Statistical Analysis 
Characteristics of the study population are presented as means and proportions and 
stratified by sex, diabetes status and early versus late diabetes diagnosis status. Chi-square 
tests were used for categorical variables and t-tests were used for continuous variables. In 
the mortality analysis, person-time was calculated from study entry date to date of death, 
termination of health insurance coverage or December 31, 2007. In the hospitalization 
analysis, all-cause, CVD, AMI, and stroke hospitalizations were assessed separately. For 
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all-cause hospitalizations, the person-time was calculated from study entry date to date of 
first hospital admission for any cause, termination of health insurance coverage, date of 
death or March 31, 2008. For the CVD hospitalizations, date of first CVD hospital 
admission was used. Likewise for AMI and stroke hospitalizations, date of first AMI 
hospital admission and stroke hospitalization were used, respectively.   
Kaplan-Meier curves were constructed for each outcome and log rank tests were 
used to test the difference between the survival curves for those with and without diabetes 
and those diagnosed early and late. Cox proportional hazard models were used to calculate 
hazard ratios (HR) with 95% confidence intervals. The main assumption of the Cox 
proportional hazard model is the proportional hazards (PH) assumption, which assumes the 
HR is constant over time. When the PH assumption was not met, an extended Cox model 
with an interaction term between survival time and the variable failing the PH assumption 
was applied
48
. Interaction terms for diabetes and sex, early diagnosis and sex, and late 
diagnosis and sex were tested by the likelihood ratio test. When interactions were not 
significant, the analysis was not stratified by sex. All statistical analyses were performed 
using SAS version 9.2 (SAS Institute Inc., Cary, NC) software. 
 
3.3.7 Ethical Considerations 
 This study was approved by the Health Research Ethics Authority (HREA), the 
research ethics board responsible for reviewing research on human subjects in 
Newfoundland and Labrador (Appendix C). Approval to access data from the 
Newfoundland and Labrador Centre for Health Information was approved by the Centre’s 
Secondary Uses Committee (Appendix D).  
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3.4 Results 
The study sample consisted of 73,783 individuals; mean age at baseline was 60.1 
years (SD=14.3). There were almost equal numbers of males and females, 37,790 (51.2%) 
and 35,993 (48.8%), respectively. About half (53.9%) of the study sample lived in a rural 
area. Over the ten-year study period, 11,385 (15.4%) individuals died and the mean age at 
death was 77.9 years (SD=11.0).  
Characteristics of the study sample by diabetes status are presented in Table 3.1. 
For males, 20.5% (n=7,751) had diabetes while 20.6% (n=7,401) of females had diabetes.  
The mean age at baseline was similar for males and females with and without diabetes. 
More males without diabetes lived in a rural area compared to males with diabetes 
(p<0.01). However, more females with diabetes lived in a rural area compared to females 
without diabetes (p<0.01). Both males and females with diabetes where more likely to die, 
be younger at death and be admitted to hospital than those without diabetes (p<0.01). When 
admitted to hospital, females with diabetes had a longer mean length of stay compared to 
females without diabetes (7.0 and 5.5, p<0.01, respectively). Males with diabetes also had a 
longer length of stay compared to males without diabetes (6.4 and 5.6, p<0.01, 
respectively). 
Characteristics of the diabetes sample by early and late diagnosis status are 
presented in Table 3.2. Both males and females diagnosed late with diabetes were 
significantly older at the time of diagnosis than those diagnosed early (p<0.01). Males and 
females diagnosed late with diabetes were more likely to be deceased at the end of the 
study period compared to those diagnosed early (p<0.01). Those diagnosed early were 
younger at death compared to those diagnosed late (p<0.01). During the study period, when  
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Table 3.1: Characteristics of the study sample stratified by diabetes status for males and females 
 Males (n = 37,790) Females (n = 35,993) Total (n = 73,783) 
 No Diabetes       
(n = 30,039) 
Diabetes          
(n = 7,751) 
p-
value
1
 
No Diabetes       
(n = 28,592) 
Diabetes          
(n = 7,401) 
p-
value
1
 
No Diabetes            
(n = 58,631) 
Diabetes                  
(n = 15,152) 
p-
value
1
 
Mean Age at 
baseline (yrs)  
59.4 (SD=13.4) 59.2 (SD=13.4) 0.289 60.9 (SD=15.1) 60.6 (SD=15.2) 0.109 60.1 (SD=14.3) 
 
59.9 (SD=14.3) 0.059 
% Residing in 
Rural area 
53.6% (16,913) 50.4% (3,906) <0.01 52.5% (15,007) 52.4% (3,879) 0.646 54.6% (31,984) 51.4% (7,785) <0.01 
% Deceased at 
Study End 
14.5% (4,360) 23.8% (1,842) <0.01 12.1% (3,471) 23.1% (1,712) <0.01 13.4% (7,831) 23.5% (3,554) <0.01 
Mean Age at 
Death (yrs) 
76.5 (SD=10.2) 74.1 (SD=11.0) <0.01 81.3 (SD=10.7) 78.3 (SD=11.2) <0.01 78.7 (SD=10.7) 76.1 (SD=11.3) <0.01 
CCI          
   0 96.6% (29,017) 95.5% (7,406) <0.01 97.3% (27,825) 96.0% (7,107) <0.01 96.9% (56,842) 95.8% (14,513) <0.01 
   1-2 2.6% (781) 3.4% (265)  2.1% (612) 3.1% (226)  2.4% (1,393) 3.2% (491)  
   3+ 0.8% (241) 1.0% (80)  0.5% (155) 0.9% (68)  0.7% (396) 1.0% (148)  
SES quintile          
   1 (lowest) 20.5% (6,154) 18.6% (1,442) <0.01 19.2% (5,486) 22.8% (1,687) <0.01 19.9% (11,640) 20.7% (3,129) <0.01 
   2 20.2% (6,079) 21.0% (1,625)  19.4% (5,539) 20.8% (1,536)  19.8% (11,618) 20.9% (3,161)  
   3 20.0% (6,012) 19.3% (1,498)  20.2% (5,784) 20.1% (1,488)  20.1% (11,796) 19.7% (2,986)  
   4 19.7% (5,930) 21.0% (1,631)  20.0% (5,712) 19.2% (1,424)  19.9% (11,642) 20.2% (3,055)  
   5 (highest) 19.5% (5,864) 20.1% (1,555)  21.2% (6,071) 17.1% (1,266)  20.4% (11,935) 18.6% (2,821)  
Hospitalizations          
  All-Cause        58.5% (17,576) 72.3% (5,602) <0.01 59.5% (17,012) 74.6% (5,518) <0.01 59.0% (34,588) 73.4% (11,120) <0.01 
  CVD 17.5% (5,261) 28.9% (2,238) <0.01 12.3% (3,517) 22.9% (1,694) <0.01 15.0% (8,778) 26.0% (3,932) <0.01 
  AMI                   6.0% (1,055) 8.6% (479) <0.01 3.4% (584) 6.1% (335) <0.01 4.7% (1,639) 7.3% (814) <0.01 
  Stroke 3.9% (694) 5.4% (302) <0.01 3.0% (507) 4.8% (267) <0.01 3.5% (1,201) 5.1% (569) <0.01 
Mean Length of 
Stay (days) 
         
  All-Cause       5.6 (SD=14.5) 6.4 (SD=15.2) <0.01 5.5 (SD=14.6) 7.0 (SD=17.4) <0.01 5.6 (SD=14.5) 6.7 (SD=16.4) <0.01 
  CVD 8.7 (SD=16.4) 9.9 (SD=32.3) 0.102 9.5 (SD=20.6) 10.0 (SD=18.4) 0.305 9.1 (SD=18.3) 10.0 (SD=27.1) 0.020 
  AMI 9.9 (SD=12.2) 9.2 (SD=8.3) 0.251 11.1 (SD=17.2) 11.8 (SD=17.4) 0.595 10.3 (SD=14.2) 10.2 (SD=12.9) 0.882 
  Stroke   25.8 (SD=39.5) 20.8 (SD=30.3) 0.054 17.8 (SD=27.3) 24.3 (SD=84.2) 0.191 21.2 (SD=33.3) 22.7 (SD=64.7) 0.519 
1
 Significance level = 0.05 
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Table 3.2: Characteristics of the study sample stratified by early and late diabetes diagnosis status for males and females 
 Males (n = 7,751) Females (n = 7,401) Total (n = 15,152) 
 Early (n =3,034) Late (n = 4,717) p-
value
1
 
Early (n=2,601) Late (n=4,800) p-
value
1
 
Early (n=5,635) Late (n=9,517) p-
value
1
 
Mean Age at 
baseline (yrs)  
53.9 (SD=12.8) 62.6 (SD=12.7) <0.01 53.6 (SD=14.7) 64.4 (SD=14.0) <0.01 53.7 (SD=13.7) 63.5 (SD=13.4) <0.01 
% Residing in 
Rural area 
55.5% (1,684) 53.7% (2,535) 0.128 55.6% (1,447) 56.4% (2,708) 0.516 55.6% (3,131) 55.1% (5,243) 0.572 
% Deceased at 
Study End 
13.2% (401) 30.5% (1,441) <0.01 11.7% (305) 29.3% (1,407) <0.01 12.5% (706) 29.9% (2,848) <0.01 
Mean Age at 
Death (yrs) 
70.7 (SD=12.5) 75.0 (SD=10.4) <0.01 76.3 (SD=12.6) 78.7 (SD=10.8) 0.002 73.1 (SD=12.8) 76.8 (SD=10.8) <0.01 
CCI          
   0 98.1% (2,977) 94.4% (8,987) <0.01 98.0% (2,549) 95.0% (4,558) <0.01 98.1% (5,526) 94.4% (8,987) <0.01 
   1-2 1.7% (51) 4.2% (396)  1.7% (44) 3.8% (182)  1.7% (95) 4.2% (396)  
   3+ 0.2% (6) 1.6% (74)  0.3% (8) 1.3% (60)  0.2% (14) 1.4% (134)  
SES quintile          
   1 (lowest) 18.6% (565) 18.6% (877) <0.01 23.3% (606) 18.6% (877) <0.01 20.8% (1,171) 20.6% (1,958) <0.01 
   2 20.6% (624) 21.2% (1,001)  19.8% (516) 21.2% (1,001)  20.2% (1,140) 21.2% (2,021)  
   3 20.6% (624) 18.5% (874)  19.4% (504) 18.5% (874)  20.0% (1,128) 19.5% (1,858)  
   4 21.2% (644) 20.9% (987)  20.3% (527) 20.9% (987)  20.8% (1,171) 19.8% (1,884)  
   5 (highest) 19.0% (577) 20.7% (978)  17.2% (448) 20.7% (987)  18.2% (1,025) 18.9% (1,796)  
Hospitalizations          
  All-Cause        64.6% (1,960) 77.2% (3,642) <0.01 69.1% (1,798) 77.5% (3,720) <0.01 66.7% (3,758) 77.4% (7,362) <0.01 
  CVD 17.7% (538) 36.0% (1,700) <0.01 13.8% (360) 27.8% (1,334) <0.01 15.9% (898) 31.9% (3,034) <0.01 
  AMI                   7.4% (144) 9.2% (335) 0.018 3.3% (60) 7.4% (275) <0.01 5.4% (204) 8.3% (610) <0.01 
  Stroke 2.9% (57) 6.7% (245) <0.01 2.6% (47) 5.9% (220) <0.01 2.8% (104) 6.3% (465) <0.01 
Mean Length of 
Stay (days) 
         
  All-Cause       4.9 (SD=10.3) 7.2 (SD=17.2) <0.01 5.1 (SD=13.3) 8.0 (SD=19.0) <0.01 5.0 (SD=11.9) 7.6 (SD=18.2) <0.01 
  CVD 8.2 (SD=22.1) 10.4 (SD=35.0) 0.148 7.5 (SD=13.4) 10.9 (SD=19.6) <0.01 7.9 (SD=18.9) 10.6 (SD=29.1) 0.001 
  AMI 9.2 (SD=7.8) 9.2 (SD=8.5) 0.992 8.1 (SD=6.0) 12.6 (SD=18.9) 0.001 8.9 (SD=7.3) 14.3 (SD=16.4) 0.017 
  Stroke   21.2 (SD=62.9) 25.1 (SD=88.5) 0.754 24.2 (SD=35.0) 20.1 (SD=29.2) 0.458 22.5 (SD=52.0) 22.7 (SD=67.2) 0.979 
1
 Significance level = 0.05 
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considering hospitalizations for all causes males and females with a late diabetes diagnosis 
were more likely to be hospitalized (p<0.01) and have a longer length of hospital stay 
compared to those diagnosed early (p<0.01).  
Interaction terms for diabetes and sex, early diagnosis and sex, and late diagnosis 
and sex were tested by the likelihood ratio test. P-values for sex interactions are shown in 
Table 3.3. When interactions were not significant, the analysis was not stratified by sex. 
For example, the interaction terms for diabetes and sex were not significant for stroke 
mortality, all-cause hospitalization, AMI hospitalization or stroke hospitalization. 
Therefore, for these outcomes, the analysis was not stratified by sex and was analyzed for 
males and females combined.  
Rates and hazard ratios (HR) for mortality and hospitalizations by sex and diabetes 
status are shown in Table 3.4. Males with and without diabetes have higher rates of all-
cause mortality and CVD hospitalizations than females. For CVD and AMI mortality, 
males without diabetes have higher rates than females; however, females have higher rates 
when diabetes is present. After adjusting for place of residence, SES and CCI, both males 
and females with diabetes had an increased risk of dying of all-causes and dying and being 
hospitalized for CVD and AMI when compared to males and females without diabetes. The 
positive association between diabetes and all-cause mortality, CVD mortality and AMI 
mortality was stronger in females than in males. Not only was diabetes positively 
associated with all-cause mortality (HR=1.85, 95% CI 1.74-1.96), and CVD 
hospitalizations (HR=2.57, 95% CI 2.24-2.94), for females, the risk was significantly 
higher compared to their male counterparts (HR=1.59, 95% CI 1.51-1.69 and HR=1.92, 
95% CI 1.72-2.14 respectively).  
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Table 3.3: P-value for sex interaction by diabetes and early and late diabetes diagnosis 
 P-value for sex interaction 
Diabetes versus 
No Diabetes 
Early versus No 
Diabetes 
Late versus No 
Diabetes 
All-Cause Mortality <0.0001** 0.0142* 0.0006** 
CVD Mortality 0.0002** 0.0332* 0.0214* 
AMI Mortality 0.0204* 0.0319* 0.1273 
Stroke Mortality 0.7819 0.0243* 0.4548 
All-Cause Hospitalization 0.6586 0.0001** 0.0026** 
CVD Hospitalization <0.0001** 0.0177* 0.0004** 
AMI Hospitalization 0.0767 0.2002 0.0044** 
Stroke Hospitalization 0.1001 0.1327 0.2613 
**p<0.01 
*p<0.05 
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Table 3.4: Mortality and Hospitalization Rates and Adjusted Hazard Ratios (HR)
1 
by diabetes status and sex 
 
 
 
Males  Females  Total 
Diabetes No Diabetes  Diabetes No Diabetes  Diabetes No Diabetes 
All-Cause Mortality 
  Rate per 10,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
CVD Mortality 
  Rate per 10,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
AMI Mortality 
  Rate per 10,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted  HR (95% CI) 
Stroke Mortality 
  Rate per 10,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
All-Cause Hospitalization 
  Rate per 1,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted  HR (95% CI) 
CVD Hospitalization 
  Rate per 1,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
AMI Hospitalization 
  Rate per 1,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
Stroke Hospitalization 
 
375.0 (1,842) 
1.74 (1.65-1.84)** 
1.59 (1.51-1.69)** 
 
52.5 (82) 
1.46 (1.15-1.85)** 
1.50 (1.15-1.90)** 
27.9 (127) 
1.62 (1.32-1.99)** 
1.48 (1.19-1.83)** 
 
17.0 (78) 
-- 
-- 
 
242.9 (5,602) 
-- 
-- 
28.5 (418) 
2.91 (2.39-3.56)** 
1.92 (1.72-2.14)** 
 
9.3 (425) 
-- 
-- 
 
 
214.7 (4,360) 
1.00 (reference) 
1.00 (reference) 
 
35.7 (386) 
1.00 (reference) 
1.00 (reference) 
17.2 (330) 
1.00 (reference) 
1.00 (reference) 
 
9.7 (187) 
-- 
-- 
 
140.5 (17,576) 
-- 
-- 
15.0 (1,603) 
1.00 (reference) 
1.00 (reference) 
 
5.0 (985) 
-- 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
361.0 (1,712) 
2.03 (1.91-2.15)** 
1.85 (1.74-1.96)** 
 
64.3 (77) 
2.60 (2.01-3.36)** 
2.45 (1.89-3.17)** 
28.9 (130) 
2.25 (1.82-2.79)** 
1.96 (1.57-2.44)** 
 
21.0 (93) 
-- 
-- 
 
255.1 (5,518) 
-- 
-- 
24.1 (277) 
4.61 (3.57-5.94)** 
2.57 (2.24-2.94)** 
 
6.5 (297) 
-- 
-- 
 
 
177.5 (3,471) 
1.00 (reference) 
1.00 (reference) 
 
24.7 (238) 
1.00 (reference) 
1.00 (reference) 
12.8 (239) 
1.00 (reference) 
1.00 (reference) 
 
11.7 (216) 
-- 
-- 
 
145.7 (17,012) 
-- 
-- 
9.0 (871) 
1.00 (reference) 
1.00 (reference) 
 
2.9 (553) 
-- 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
368.1 (3,554) 
-- 
-- 
 
57.6 (159) 
-- 
-- 
28.4 (257) 
-- 
-- 
 
18.9 (171) 
1.77 (1.48-2.12)** 
1.62 (1.35-1.94)** 
 
248.8  (11,120) 
1.64 (1.60-1.67)** 
1.61 (1.58-1.64)** 
26.6 (695) 
-- 
-- 
 
7.9 (722) 
1.57 (1.44-1.72) 
1.61 (1.48-1.75)** 
 
 
196.5 (7,831) 
-- 
-- 
 
30.5 (624) 
-- 
-- 
15.0 (569) 
-- 
-- 
 
10.7 (403) 
1.00 (reference) 
1.00 (reference) 
 
143.0  (34,588) 
1.00 (reference) 
1.00 (reference) 
12.1 (2,474) 
-- 
-- 
 
4.0 (1,538) 
1.00 (reference) 
1.00 (reference) 
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  Rate per 1,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
5.7 (265) 
-- 
-- 
3.1 (608) 
-- 
-- 
5.2 (236) 
-- 
-- 
2.3 (445) 
-- 
-- 
5.5 (501) 
1.58 (1.42-1.76)** 
1.31 (1.17-1.46)** 
2.7 (1,053) 
1.00 (reference) 
1.00 (reference) 
Note: Missing HRs indicate lack of significant group by sex interaction
 
1
 Adjusted for region of residence, SES quintile and CCI. 
*p<0.05 
**p<0.01 
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Rates and hazard ratios (HR) for mortality and hospitalizations by sex and early and 
late diabetes diagnosis status are shown in Table 3.5. The reference group used included 
individuals without diabetes for all analyses. An early diagnosis does not appear to have an 
impact on all-cause, CVD, AMI or stroke mortality. However, the hospitalization results 
suggest that an early diagnosis does increase the risk of all-cause, CVD, and AMI 
hospitalizations compared to individuals without diabetes. After adjusting for covariates, 
males diagnosed late with diabetes had an increased risk of all-cause and CVD mortality 
and hospitalizations compared to males without diabetes. Similar findings were found for  
females.  Not only was a late diabetes diagnosis positively associated with CVD mortality 
(HR=6.54, 95% CI 4.80-8.91) and CVD hospitalizations (HR=5.22, 95% CI 4.31-6.33) for 
females, the risk was significantly higher compared to their male counterparts (HR=3.44, 
95% CI 2.47-4.79 and HR=3.33, 95% CI 2.80-3.95, respectively). 
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Table 3.5: Mortality and Hospitalization Rates and Adjusted Hazard Ratios (HR)
 1
 by early and late diabetes diagnosis status 
and sex 
 
 
 
Males  Females  Total 
Early
2 Late2  Early
2 Late2  Early
2 Late2 
All-Cause Mortality 
  Rate per 10,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
CVD Mortality 
  Rate per 10,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
AMI Mortality 
  Rate per 10,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
Stroke Mortality 
  Rate per 10,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
All-Cause Hospitalization 
  Rate per 1,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
CVD Hospitalization 
  Rate per 1,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
AMI Hospitalization 
  Rate per 1,000 (n)  
 
192.4 (401) 
-- 
-- 
34.7 (43) 
-- 
-- 
 
9.0 (18) 
-- 
-- 
4.5 (9) 
-- 
-- 
 
168.8 (1,960) 
1.18 (1.13-1.24)** 
1.17 (1.11-1.23)** 
 
23.4 (277) 
-- 
-- 
 
7.0 (142) 
 
509.4 (1,441) 
2.37 (2.23-2.52)** 
2.09 (1.97-2.23)** 
120.0 (39) 
3.39 (2.44-4.71)** 
3.44 (2.47-4.79)** 
 
42.7 (109) 
-- 
-- 
26.6 (69) 
-- 
-- 
 
318.0 (3,642) 
2.05 (1.98-2.12)** 
1.89 (1.81-1.95)** 
 
49.6 (141) 
3.34 (2.81-3.96)** 
3.33 (2.80-3.95)** 
 
11.1 (283) 
  
169.8 (305) 
-- 
-- 
30.5 (28) 
-- 
-- 
 
12.1 (21) 
-- 
-- 
12.2 (21) 
-- 
-- 
 
193.9 (1,798) 
1.30 (1.23-1.36)** 
1.26 (1.20-1.32)** 
 
16.8 (151) 
-- 
-- 
 
3.3 (59) 
 
477.5 (1,407) 
2.68 (2.52-2.85)** 
2.38 (2.23-2.53)** 
175.1 (49) 
7.14 (5.25-9.71)** 
6.54 (4.80-8.91)** 
 
39.5 (109) 
-- 
-- 
26.5 (72) 
-- 
-- 
 
301.1 (3,720) 
1.91 (1.84-1.98)** 
1.75 (1.69-1.82)** 
 
50.5 (126) 
5.73 (4.76-6.91)** 
5.22 (4.31-6.33)** 
 
8.5 (238) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182.0 (706) 
0.92 (0.85-0.99)* 
0.91 (0.84-0.98)* 
32.9 (71) 
1.07 (0.84-1.37) 
0.99 (0.77-1.28) 
 
10.4 (39) 
0.70 (0.50-0.96)* 
0.70 (0.51-0.97)* 
8.1 (30) 
0.75 (0.52-1.09) 
0.74 (0.51-1.08) 
 
179.9 (3,758) 
-- 
-- 
 
20.5 (428) 
1.70 (1.53-1.88)** 
1.64 (1.48-1.82)** 
 
5.3 (201) 
 
493.1 (2,848) 
-- 
-- 
145.5 (88) 
-- 
-- 
 
41.0 (218) 
2.72 (2.33-3.18)* 
2.34 (1.98-2.76)* 
26.5 (141) 
2.49 (2.06-3.02)** 
2.21 (1.81-2.70)** 
 
309.3 (7,362) 
-- 
-- 
 
50.0 (267) 
-- 
-- 
 
9.8 (521) 
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Note: Missing HRs indicate lack of significant group by sex interaction
 
1
 Adjusted for region of residence, SES quintile and CCI. 
2
 The reference group used included individuals without diabetes. 
*p<0.05 
**p<0.01 
 
 
 
 
 
 
 
 
 
 
 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
Stroke Hospitalization 
  Rate per 1,000 (n) 
  Unadjusted HR (95% CI) 
  Adjusted HR (95% CI) 
-- 
-- 
2.6 (53) 
-- 
-- 
1.63 (1.43-1.86)** 
1.64 (1.44-1.88)** 
8.1 (212) 
-- 
-- 
-- 
-- 
2.6 (46) 
-- 
-- 
2.24 (1.93-2.61)** 
2.15 (1.85-2.51)** 
6.9 (190) 
-- 
-- 
1.14 (0.99-1.32) 
1.27 (1.09-1.48)** 
2.6 (99) 
0.82 (0.67-1.01) 
0.95 (0.78-1.17) 
-- 
-- 
7.5 (402) 
2.05 (1.82-2.29)** 
1.98 (1.76-2.23)** 
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Kaplan-Meier curves and log rank tests show that males and females without 
diabetes had lower risks of all-cause mortality (p<0.01; Figure 3.2 and 3.3) and CVD 
hospitalizations (p<0.01; Figure 3.4 and 3.5) compared to males and females with diabetes. 
When comparing individuals diagnosed late with diabetes to those without diabetes, 
Kaplan-Meier curves and log rank tests show that males and females without diabetes had 
lower risks of CVD mortality (p<0.01; Figure 3.6 and 3.7) and CVD hospitalizations 
(p<0.01; Figure 3.8 and 3.9) compared to males and females diagnosed late with diabetes.   
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Figure 3.2: Kaplan-Meier curves for all-cause mortality among males with and without diabetes 
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   Males without Diabetes  
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Figure 3.3: Kaplan-Meier curves for all-cause mortality among females with and without diabetes 
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   Females without Diabetes
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Figure 3.4: Kaplan-Meier curves for CVD hospitalizations among males with and without diabetes 
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Figure 3.5: Kaplan-Meier curves for CVD hospitalizations among females with and without diabetes 
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Figure 3.6: Kaplan-Meier curves for CVD mortality among males diagnosed late with diabetes and males without diabetes 
 
 
 
 
 
 
   Males Diagnosed Late with Diabetes              
 
  Males without Diabetes
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Figure 3.7: Kaplan-Meier curves for CVD mortality among females diagnosed late with diabetes and females without diabetes 
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Figure 3.8: Kaplan-Meier curves for CVD hospitalizations among males diagnosed late with diabetes and males without 
diabetes 
 
 
 
 
 
   Males Diagnosed Late with Diabetes              
 
  Males without Diabetes
  
  
   
 104 
 
Figure 3.9: Kaplan-Meier curves for CVD hospitalizations among females diagnosed late with diabetes and females without  
                diabetes 
 
 
   Females Diagnosed Late with Diabetes            
 
  Females without Diabetes
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3.5 Discussion 
In this population-based retrospective cohort study, mortality and hospitalizations 
for males and females with and without diabetes and those diagnosed early and late with 
diabetes were examined. After adjusting for covariates, not only was diabetes positively 
associated with all-cause mortality and CVD hospitalizations for females, the risk was 
significantly higher compared to their male counterparts. After adjusting for covariates, an 
early diagnosis does not appear to have an impact on all-cause, CVD, AMI or stroke 
mortality. However, the hospitalization results suggest that an early diagnosis does increase 
the risk of all-cause, CVD, and AMI hospitalizations compared to individuals without 
diabetes. Males and females diagnosed late with diabetes had an increased risk of all-cause 
mortality, CVD mortality, and CVD hospitalizations compared to those without diabetes. 
The risk of CVD mortality and hospitalizations for females diagnosed late compared to 
females without diabetes was significantly higher when compared to their male 
counterparts. While diabetes increases the risk of mortality and hospitalizations for both 
males and females, females are at a higher risk than males. CVD, in particular, has a 
greater impact on females with diabetes than males, especially when diabetes is diagnosed 
late.  
Previous studies have also found that individuals with diabetes have an increased 
risk of mortality and morbidity related to all-causes, CVD, AMI, and stroke compared to 
individuals without diabetes
12, 17-19
. This study also found that females with diabetes had an 
increased risk of all-cause mortality, CVD mortality and CVD hospitalizations compared to 
females without diabetes and this was significantly higher compared to their male 
counterparts. The majority of previous studies have supported the claim that females with 
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diabetes are at a greater risk of mortality and morbidity than males with diabetes
 12, 17, 19-24
. 
In addition, the results of this study show that CVD has a greater impact on females than 
males with diabetes.  
It is not known why females with diabetes have an increased risk of mortality and 
hospitalizations compared to males with diabetes. More males are diagnosed with 
diabetes
4
, and are diagnosed at lower BMI levels than females, which suggest males may 
be more susceptible to diabetes than females
49
. One explanation is that CVD risk factors 
have a stronger impact on females than males. The Strong Heart Study compared 
differences in diabetes risk factors in males and females aged 45-74. Differences in waist-
to-hip ratio, HDL cholesterol, apolipoprotein (apo)B, apoA1, fibrinogen and LDL size 
between females with diabetes and those without diabetes were greater than differences for 
males
20
. Juutilainen et al.
23
 investigated possible explanations for the stronger effect that 
diabetes has on the risk of coronary heart disease (CHD) in females compared to males. 
Risk factors in the presence of diabetes were greater in females than in males at baseline. 
During follow-up, these risk factors were stronger contributors to diabetes-related CHD 
risk in females than in males. Moreover, Homko et al.
50
 examined differences in CVD risk 
factors and risk perception among males and females with diabetes. Although HbA1C and 
fasting plasma glucose levels were similar, females with diabetes had higher cholesterol 
levels and were less likely to meet LDL and blood pressure targets. While males and 
females had similar knowledge of CVD, females perceived their risk of CVD to be higher 
than males did. Also, females have an elevated risk of MI and stroke before they are 
clinically diagnosed with diabetes and it has been suggested that the risk of CVD in 
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females begins to increase at least 15 years before they are clinically diagnosed with 
diabetes
51
. 
Another possible explanation is that CVD risk factors are less aggressively treated 
in females. Females with diabetes are less likely than males to have optimal blood glucose 
control (HbA1C <7%), be prescribed aspirin and lipid-lowering medications and to achieve 
recommended blood pressure and LDL cholesterol levels
52, 53
. In addition, results from the 
NL Component of the Canadian Community Health Survey show that females with 
diabetes are less likely to be taking insulin, have their HbA1C levels tested and be 
prescribed aspirin and blood cholesterol medication compared to males with diabetes
54
. 
Barrett-Connor et al.
55
 suggested that higher cardiovascular mortality risk observed 
in females with diabetes is a result of the larger survival advantage females have when 
diabetes is not present. This could explain the CVD and AMI mortality results found in this 
study. However, this does not explain the results for all-cause mortality and CVD 
hospitalizations as males had higher rates than females whether diabetes was present or not. 
In addition, risk of all-cause mortality and CVD hospitalizations where higher for females 
than males.      
Results from randomized controlled trials (RCT) have found that the risk of 
microvascular complications can be reduced with intensive glucose control; however, the 
effect on macrovascular complications have been less clear
10, 11
. The UK Prospective 
Diabetes Study (UKPDS), Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation (ADVANCE), Veterans Affairs 
Diabetes Trial (VADT) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
are RCT’s that have been conducted to compare the effect of intensive glucose control 
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versus standard glucose control on CVD mortality and hospitalizations in patients with 
diabetes. These trials found that CVD events can be reduced with intensive glucose control; 
however, no significant effect on CVD mortality or all-cause mortality was found
10, 56-58
.
  
However, the UKPDS examined whether intensive glucose control with Metformin 
reduces the risk of microvascular and macrovascular complications in overweight patients 
with newly diagnosed type 2 diabetes. Patients treated with Metformin, compared with the 
conventional treatment group, had a 32% lower risk of developing any diabetes-related 
endpoint (microvascular and macrovascular complications), a 42% lower risk for diabetes-
related mortality, and a 36% lower risk for all-cause mortality
11
. 
Intensive glucose control however, may cause adverse outcomes in some patients. 
The ACCORD trial was stopped early due to higher mortality in the intensive glucose 
control group compared to the standard control group
57
. Also, the ADVANCE, ACCORD, 
VADT, and UKPDS trials showed higher rates of hypoglycemic episodes and weight gain 
in the group that was treated more intensively
56-58
. A recent meta-analysis of RCT’s found 
limited benefits of intensive glucose lowering treatments on all-cause and CVD mortality, 
and concluded that the harm associated with hypoglycemia may offset any potential 
benefits of intense glucose control
59
. Alternatively, the UKPDS 10-year post-trial follow-
up found that significant reduction in microvascular risk persisted, and significant 
reductions in myocardial infarction and all-cause mortality were seen in the intensive-
control group during follow-up. The authors used the term ‘legacy effect’ to describe the 
continued benefit of intensive treatment
60
. Also, when patients were intensively treated 
with Metformin in the UKPDS, Metformin did not induce weight gain and was associated 
with less episodes of hypoglycaemia than sulphonylurea or insulin therapy
11
. 
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Patients in the ADVANCE, VADT and ACCORD trials had diabetes for a number 
of years before entering the trial, whereas patients in the UKPDS where newly diagnosed. 
This could suggest that the same HbA1C target and treatment plan should not be applied to 
all patients with diabetes. Perhaps the focus should not only be on glucose control but on 
all CVD risk factors. The Canadian Diabetes Association Clinical Practice Guidelines 
provide recommended targets for glycemic control and suggest that treatment strategies 
should be individualized with consideration given to presence of risk factors
61
. Early and 
aggressive treatment has been suggested for patients that are newly diagnosed and do not 
have a history of CVD while less aggressive treatment may be suitable for older patients 
with a longer duration and a history of CVD
62
. However, this recommendation does not 
take into account the greater CVD risk that females with diabetes have. Perhaps a better 
approach would be to consider different treatment plans based on sex and timing of 
diabetes diagnosis.  
 
3.5.1 Limitations 
There are several strengths and limitations in this study. First of all, this was a large 
population-based cohort study with a long follow-up time. In addition, multiple outcomes 
were studied and administrative data was used to identify hospital separations and deaths. 
However, there are also several limitations that need to be addressed. Firstly, the CCDSS 
diabetes case definition does not differentiate between type 1 and type 2 diabetes. Since 
most individuals developing diabetes as adults will have type 2 diabetes
1
 it is unlikely to 
have impacted the results in a major way.  
Furthermore, the CCDSS diabetes case definition uses physician claims data. In 
Newfoundland and Labrador, one-third of the province’s physicians are paid on a salary 
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basis
63
 and these physicians are not required to submit medical claims so information on 
these visits is not captured. Some misclassification could have occurred as individuals with 
diabetes could have been classified as not having diabetes because a salaried physician 
provided most of their care. This also has the potential to impact findings by place of 
residence (urban/rural), as rural areas are largely serviced by salaried physicians. However, 
results from the Newfoundland and Labrador Component of the Canadian Community 
Health Survey show that individuals living in rural areas are less likely to have a physician 
visit in the last 12 months than individuals living in urban areas
64
. Also, individuals in rural 
areas are more likely to have a hospital admission in the last 12 months than those living in 
urban areas
65
. This suggests that the number of individuals with diabetes that are missed in 
rural areas is not substantial.  
Also, early and late diabetes diagnosis was determined by linking records for those 
with diabetes to the MCP and CDMS data to identify when hospital and physician visits for 
diabetes related comorbidities or complications occurred and these were compared to the 
diabetes case dates. The range of 6 months before and after diagnosis was used to define 
early and late diabetes diagnosis. Some misclassification could have occurred as 
comorbidities or complications could have developed outside the 6 month range. 
Conditions such as cardiovascular disease, stroke, and coronary artery disease have similar 
risk factors as diabetes and could be diagnosed at the same time or before diabetes is 
diagnosed. Since many definitions of early and late diabetes diagnosis were tested and 
there was little change in the sample distribution across definitions, we feel that the range 
of 6 months before or after diagnosis is a good definition of early and late diabetes 
diagnosis. However, more research into when comorbidities and complications of diabetes 
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develop is needed. In addition, the definition of early and late depends on conditions 
identified through healthcare services covered by MCP. Conditions identified through 
healthcare services not covered by MCP could not be captured. Optometry services are not 
covered under MCP, therefore retinopathy would not be captured unless it was included in 
the CDMS data. 
 Also, the list of conditions used in the early and late case definition is extensive. 
Many of these conditions could have been due to conditions other than diabetes. For 
example, it is possible that for conditions such as renal disease, amyloidosis, 
hyperlipidemia, optic nerve problems, polyneuropathies, facial nerve disorders, 
inflammatory polyneuropathy, radiculopathy, and a number of others may not be due to 
complications of diabetes. Conditions such as hypertension may also be present prior to the 
onset of diabetes. For the CCDSS cohort, hypertension was the condition that defined a late 
diagnosis in 71.1% of cases. Misclassification bias is a possibility and future research 
should aim to not only test different case definitions of early and late diabetes diagnosis but 
also to include fewer conditions in the definitions. 
Individuals hospitalized for CVD, AMI or stoke before 1994/95 cannot be 
identified using the existing database. However, a washout period from January 1, 1995 to 
March 31, 1997 was applied to exclude those that had a CVD, AMI or stroke event prior to 
the study start date and to help ensure that only newly diagnosed cases of diabetes were 
included. 
Also, information on CVD risk factors was not available and thus could not be 
controlled for in the analysis. Finally, place of residence used in this study was the place of 
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residence at the beginning of the study period. Movement from a rural to an urban region 
and vice versa throughout the ten-year study period could have occurred. 
 
3.6 Conclusion 
In conclusion, the results of this study show that females with diabetes have a 
greater risk of mortality than males with diabetes. CVD has a greater impact on females 
than males with diabetes, especially when diagnosed at a later stage. Different management 
strategies could be considered for males and females and for those diagnosed early and late 
with diabetes.  
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4.1 Abstract        
Objective: To describe how family physicians diagnose, treat and manage type 2 diabetes. 
A secondary objective was to identify if there were any differences in how male and female 
family physicians diagnose, treat and, manage individuals with type 2 diabetes.  
 
Methods: A 28-item questionnaire, which included both open and closed ended questions 
was developed and mailed to all family physicians and general practitioners practicing in 
Newfoundland and Labrador (NL). Descriptive statistics were used to describe the 
characteristics of the survey respondents and to present results from the survey. 
 
Results: Only 5.4% of family physicians reported that none of their patients had 
complications at the time of diagnosis. The majority of family physicians diagnose type 2 
diabetes at an FPG (Fasting Plasma Glucose) level of 7 or greater (87.2%) and 68.5% will 
initiate a pharmacologic treatment at this level or greater. Only 31.3% of family physicians 
record a patient’s weight at every visit while 91.2% checked a patient’s blood pressure at 
every visit. The majority of family physicians reported counselling patients with type 2 
diabetes on weight management (96.9%), healthy eating habits (94.4%), physical activity 
(98.8%) and smoking cessation (98.1%). The majority of family physicians reported 
screening high-risk patients for type 2 diabetes (98.1%); however, only 69.6% agreed that 
individuals aged 40 years and older with no risk factors should be screened for type 2 
diabetes every 3 years. Male and female family physicians were similar in their diagnosis, 
treatment and management practices and in their attitudes toward diabetes. However, male 
family physicians were more likely than female family physicians to agree that HbA1C 
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(Glycated Hemoglobin A1C) is useful for screening (32.7% versus 16.0%, p<0.05) and 
male family physicians use HbA1C as a screening method more than female family 
physicians (45.9% versus 23.5%, p<0.05). 
 
Conclusion: The majority of family physicians in NL have patients with complications 
present when they are diagnosed with diabetes. Even though family physicians have 
positive attitudes toward diabetes management, risk factors for diabetes complications like 
patient’s body weights are not monitored to the extent blood pressure is. Family physicians 
need to monitor all risk factors for diabetes complications closely in an attempt to prevent 
progression to serious complications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122 
4.2 Introduction 
 Type 2 diabetes is a progressive disorder, which often has a gradual onset and a 
long asymptomatic phase. As a result, hyperglycemia can be present for many years
1
 and 
type 2 diabetes can be present for up to 12 years before being clinically diagnosed
2, 3
. 
Diabetes is a complex condition and the development of diabetes related complications 
presents an immense challenge for family physicians. Symptoms of diabetes are variable 
and are not present for all patients. Some can develop slowly and therefore may not be 
noticed for years. Symptoms such as fatigue, frequent urination and excessive thirst are 
often ignored or can often be attributed to less serious conditions
4, 5
. 
Primary care providers often consider diabetes as harder to treat compared to other 
conditions like hypertension and angina
6
. Not all newly diagnosed patients will have 
complications at the time of diagnosis though some will. Fortunately, the potential does 
exit to prevent or at least delay the onset of type 2 diabetes as the findings of several 
randomized control trials have suggested that both lifestyle and pharmacologic 
interventions in adults are effective
7-10
. In addition to preventing diabetes, it is also possible 
to reduce diabetes related microvascular complications through intensive blood glucose 
control. Results from the United Kingdom Prospective Diabetes Study (UKPDS) have 
shown that intensive blood glucose control reduces diabetes related microvascular 
complications
10, 11
.  
Not only does Newfoundland and Labrador (NL) have the highest age-standardized 
prevalence of diabetes in Canada
12
, the age-standardized mortality and hospitalization rates 
for diabetes complication such as cardiovascular disease (CVD), acute myocardial 
infarction (AMI) and stroke are among the highest in the country
13, 14
. Family physicians 
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have an opportunity to detect type 2 diabetes at the earliest possible stage and to provide 
appropriate management and treatment strategies in an effort to prevent serious 
complications. Early detection of diabetes is important since appropriate management 
strategies can be implemented. Therefore, it is important to identify how family physicians 
are diagnosing, treating, and managing type 2 diabetes.  
 
4.2.1 Research Objectives 
The main objective of this study was to describe how family physicians diagnose, 
treat and manage type 2 diabetes. A secondary objective was to identify if there were any 
differences in how male and female family physicians diagnose, treat, and manage 
individuals with type 2 diabetes. 
 
4.3 Methods  
4.3.1 Study Design and Study Sample 
 This was a descriptive cross-sectional study. Data were collected through a survey 
developed specifically for this study. Names and mailing addresses of all physicians 
practicing in NL (n=1110) were obtained from the Newfoundland and Labrador Medical 
Association in May 2009. Of the 1110 addresses provided, one physician’s mailing address 
was listed as another province so he/she was excluded, leaving 1109 physician addresses. 
Mailing addresses were missing or incomplete for 13 physicians so they were also 
excluded, leaving 1096 physician addresses. Only family physicians and general 
practitioners were included leaving 509 physicians practicing within NL that met the 
inclusion criteria. 
 124 
4.3.2 Questionnaire Development 
 Data were collected using a 28-item self-administered questionnaire, which 
included both open and closed ended questions. The questionnaire was developed to assess 
how family physicians diagnose, treat, and manage type 2 diabetes. 
 
4.3.3 Data Collection 
The survey was pilot tested with four family physicians between March 2009 and 
May 2009. Based on feedback, questions were deleted, reworded or reordered. A letter of 
information, the survey itself and a stamped return envelope were mailed to all general 
practitioners in the province (Appendix E). A second survey mail out was sent to all 
general practitioners four weeks after the first. The first mail out occurred in September 
2009 and the second occurred in November 2009. 
 
4.3.4 Statistical Analysis 
 
Data were entered and analyzed using SPSS (SPSS Inc., Chicago IL). Descriptive 
statistics were used to describe the characteristics of the survey respondents and to present 
results from the survey. Percentages reflect the percentage of total respondents answering 
the survey question. Chi square tests were used to determine if sex and practice location 
differences existed. A significance level is p<0.05 was used to establish statistical 
significance.  
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4.3.5 Ethical Considerations 
 This study was approved by the Health Research Ethics Authority (HREA), the 
research ethics board responsible for reviewing research on human subjects in 
Newfoundland and Labrador (Appendix C). Since the surveys that were returned were 
anonymous this ensured the confidentiality and privacy of all study participants. All study 
data were stored on a secure server at the Newfoundland and Labrador Centre for Health 
Information. 
 
 
4.4 Results 
 
Surveys were mailed to 509 family physicians and general practitioners practicing 
within NL. Of the 509 surveys mailed, 26 were returned due to invalid addresses leaving a 
total of 483 potential respondents. A total of 161 (33.3%) surveys were completed and 
returned.  
Demographic characteristics of the survey respondents are presented in Table 4.1. 
Mean age of respondents was 47.5 years (SD=10.9) and the majority of those that 
responded were male (68.3%). Years of practice ranged from one to 43 years with a mean 
of 19.4 (SD=11.9) years in practice. About half (48.5%) of family physicians had been 
practicing for more than 20 years with. The majority of family physicians practiced in a 
group setting (52.2%) while 31.7% practiced in a hospital or health centre and 10.5% in a 
private practice. The majority of family physicians responding practiced in an urban setting 
(72.3%) and were paid on a fee-for-service billing schedule (64.0%).  
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Table 4.1: Characteristics of Family Physician Survey Respondents and Practice 
Characteristics in NL  
 
 n  % 
Sex (n=161)
1
   
       Male 110  68.3% 
       Female 51  31.7% 
Number of years practicing (n=161)   
       1 – 5 23  14.3% 
    6 – 10 30  18.6% 
    11 – 20 30  18.6% 
    > 20 78  48.5% 
Type of Practice (n=161)   
       Hospital/Health Centre 51  31.7% 
       Private 17  10.5% 
       Group Practice 84  52.2% 
       Other 9  5.6% 
Practice Location (n=159)   
       Rural (≤ 5,000) 44  27.7% 
    Urban (> 5,000) 115  72.3% 
Billing Structure (n=161)
2
   
       Fee-for-service 103  64.0% 
    Salaried academic physician 11  6.8% 
    Salaried community based physician 42  26.1% 
    Other 5  3.1% 
Provide care to patients with type 2 diabetes  (n=160) 156  97.5% 
Involved in the Chronic Disease Management  Diabetes Collaborative (n=157) 41  26.1% 
Percentage of patients with type 2 diabetes (n=150)   
       < 10% 36  24.0% 
    10 – 19 60  40.0% 
    20 – 49 44  29.3% 
    50% or more 10  6.7% 
Percentage of type 2 diabetes patients with complications at diagnosis (n=147)   
       0% 8  5.4% 
    1 – 9% 69  46.9% 
    10 - 24% 45  30.6% 
    25 - 49% 14  9.5% 
    50% or more 11  7.5% 
Percentage of type 2 diabetes patients who receive care from a specialist (n=140)   
       < 10% 52  37.1% 
    10 - 19% 32  22.9% 
    20 - 49% 34  24.3% 
    50% or more 22  15.7% 
1 
In 2009, when this survey was conducted, 30.7% of practicing physicians in NL were 
female and 69.3% were male, according to the Newfoundland and Labrador Medical 
Association.  
2
 In 2009, when this survey was conducted, 59.8% of practicing physicians in NL were 
paid on a fee-for-service schedule and 37.1% were salaried, according to the 
Newfoundland and Labrador Medical Association.  
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When asked if they provided care to patients with type 2 diabetes, 97.5% indicated 
they did and 26.1% said they were involved in the Chronic Disease Management Diabetes 
Collaborative. When asked what percentage of their patients had type 2 diabetes, 24.0% of  
Family physicians said less than 10%; 40.0% said between 10 and 19%; 29.3% said 
between 20 and 49%; and, 6.7% of family physicians said that 50% or more of their 
patients had type 2 diabetes. When asked what percentage of their patients had 
complications at the time of diagnosis only 5.4% of family physicians said none of their 
patients had complications at the time of diagnosis. Almost 47% said between 1 and 9% 
while 30.6% said between 10 and 24% of patients had complications at diagnosis. When 
asked what percentage of their type 2 diabetes patients received care from a specialist, 
37.1% said that less than 10%; 22.9% said between 10% and 19%; 24.3% said between 
20% and 49%; and, 15.7% said 50% or more. 
The diagnosis, treatment and management practices of family physicians are shown 
in Table 4.2. Fasting plasma glucose (FPG) was the most frequent method used to screen 
patients for diabetes (98.8%) followed by 2 hr plasma glucose (2hPG) in a 75-g oral 
glucose tolerance test (56.9%). The majority of family physicians surveyed stated they 
would make a type 2 diabetes diagnosis when the FPG level is 7 or greater (87.2%). When 
asked about initiating a pharmacologic treatment, 68.5% would begin this treatment when 
the FPG level is 7 or greater while 19.6% stated waiting until the FPG level is 10 or 
greater. When asked what glycated hemoglobin A1C (HbA1C) is useful for, 89.4% of 
family physicians said blood glucose monitoring, 74.4% said treatment and 27.5% said 
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Table 4.2: Diagnosis, Treatment and Management Practices of Family Physicians in  
      NL 
 
 n (%) % 
Which screening method do you use (n=160)   
        Fasting plasma glucose (FPG) 158  98.8% 
    Casual plasma glucose (PG) 28  17.5% 
    2 hr plasma glucose (2hPG) in a 75-g oral  
    glucose tolerance test (OGTT) 
91  56.9% 
    Glycosylated haemoglobin (HbA1C) 62  38.8% 
       Other
1
 7  4.3% 
At what FPG level do you usually make a diagnosis of type 2 diabetes 
(n=156) 
  
       6 or greater 16  10.3% 
       7 or greater 136  87.2% 
   10 or greater 4  2.6% 
At what FPG level do you usually initiate a pharmacologic treatment (n=143)   
       6-6.9 5  3.5% 
       7 or greater 98  68.5% 
   10 or greater 28  19.6% 
   Need to consider other factors 12 8.4% 
Measuring Glycosylated hemoglobin (HbA1C) is useful for:    
       screening (n=160) 44  27.5% 
       treatment (n=160) 119  74.4% 
       Blood glucose monitoring (n=160) 143  89.4% 
Do you recommend home glucose monitoring to    
your type 2 diabetes patients (n=158) 
157  99.4% 
For patients with type 2 diabetes, do you record their weight at every visit 
(n=160) 
50  31.3% 
For patients with type 2 diabetes, do you check their blood pressure at every 
visit (n=159) 
145  91.2% 
Do you counsel patients on the following topics (n=160)   
      Weight management 157  98.1% 
      Healthy eating habits 148  92.5% 
      Physical activity 156  97.5% 
      Smoking cessation 158  98.8% 
      Other
2
 18  11.3% 
Do you counsel type 2 diabetes patients on the following topics (n=160)  
 
 
 
      Weight management 155  96.9% 
      Healthy eating habits 151  94.4% 
      Physical activity 158  98.8% 
      Smoking cessation 157  98.1% 
      Other
3
 25  15.6% 
1
Other includes 2 hr PG, urinelysis and 2h postprandial ; 
2
Other includes alcohol, body image, self esteem, 
medications, heredity, cholesterol, stress reduction, control of comorbidities;
3
 Other includes alcohol, 
medications, diabetes complications, foot care, glucose monitoring, cholesterol, cancer screening, stress 
reduction.
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screening. Ninety-nine percent of family physicians said they recommend home glucose 
monitoring to their patients.  
When asked about diabetes management practices, only 31.3% of family physicians 
record their patient’s weight at every visit while 91.2% of family physicians checked their 
patient’s blood pressure at every visit. The majority of family physicians reported 
counselling patients with type 2 diabetes on weight management (96.9%), healthy eating 
habits (94.4%), physical activity (98.8%) and smoking cessation (98.1%). 
Table 4.3 shows family physician attitudes toward diabetes screening, management 
and treatment practices. Almost 84% of family physicians said they always or often use the 
2008 Canadian Diabetes Association’s Clinical Practice Guidelines as a decision support 
tool. The majority of family physicians reported that they screen high-risk patients for type 
2 diabetes (98.1%). While 71.1% of family physicians indicated that they refer patients to a 
registered dietitian, 95% said they refer type 2 diabetes patients to a registered dietitian. 
Only 69.6% of family physicians agreed that individuals 40 years of age and older with no 
risk factors should be screened for type 2 diabetes every 3 years. However, 89.4% agreed 
that screening high-risk patients is feasible in a day-to-day medical practice. In terms of 
reducing complications, 82.6% agreed that tight blood glucose control would reduce 
complications for the patient in the long term. In addition, 90.7% agreed that early 
treatment for those with impaired fasting glucose (IFG) should reduce complications in the 
long term. 
 Diagnosis, treatment and management practices of family physicians by sex are 
shown in Table 4.4, while family physician attitudes toward diabetes by sex are presented 
in Table 4.5. Male and female family physicians were similar in their diagnosis, treatment 
and management practices and in their attitudes toward diabetes. The only differences 
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found were that male family physicians were more likely than female family physicians to 
agree that HbA1C is useful for screening (32.7% versus 16.0%, p<0.05) and male family 
physicians use HbA1C as a screening method more than female family physicians (45.9% 
versus 23.5%, p<0.05). 
 
Table 4.3: Family Physician Attitudes Toward Diabetes Screening, Management and 
Treatment Practices in NL 
 
 
 
Always/Often  
    n (%) 
How often do you use the 2008 Canadian Diabetes Association’s Clinical 
Practice Guidelines as a decision support tool? (n=158) 132 (83.5%) 
How often do you screen high-risk patients for type 2 diabetes?  (n=159) 155 (98.1%) 
How often do you refer your patients to a registered dietician? (n=159) 113 (71.1%) 
How often do you refer your type 2 diabetes patients to a registered 
dietician? (n=159) 
151 (95.0%) 
 
 
Agree 
 n (%) 
According to the 2008 CDA’s Clinical Practice Guidelines, screening for 
type 2 diabetes should be performed every 3 years among individuals > 40 
years of age with no other risk factors? (n=160) 
112 (69.6%) 
Screening all high-risk patients for type 2 diabetes is feasible in a day-to-
day medical practice (n=160) 
144 (89.4%) 
Tight blood glucose control for patients with type 2 diabetes will reduce 
complications for the patient in the long term (n=160) 133 (82.6%) 
Early treatment of patients with impaired fasting glucose (IFG) will 
reduce complications in the long term? (n=161) 146 (90.7%) 
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Table 4.4: Diagnosis, Treatment and Management Practices of Family Physicians by Sex 
 
 n (%)  Yes  
Male Physicians 
(n=110) 
Female Physicians 
(n=51) 
p-value 
Do you use Fasting Plasma Glucose (FPG) as a screening method? 107 (98.2%) 51 (100%) 0.330 
Do you use Casual Plasma Glucose (PG) as a screening method? 21 (19.3%) 7 (13.7%) 0.390 
Do you use Oral Glucose Tolerance Test (OGTT) as a screening method? 62 (56.9%) 29 (56.9%) 0.390 
Do you use Glycosylated hemoglobin (HbA1C) as a screening method? 50 (45.9%) 12 (23.5%) 0.007* 
Measuring HbA1C is useful for screening. 36 (32.7%) 8 (16.0%) 0.028* 
Measuring HbA1C is useful for treatment. 85 (77.3%) 34 (68.0%) 0.213 
Measuring HbA1C is useful for blood glucose monitoring. 97 (88.2%) 46 (92.0%) 0.468 
Do you recommend home glucose monitoring? 107 (99.1%) 50 (100%) 0.495 
For type 2 diabetes patients, do you record their weight at every visit? 38 (34.5%) 12 (24.0%) 0.182 
For type 2 diabetes patients, do you check their blood pressure at every visit? 101 (91.8%) 44 (89.8%) 0.678 
Do you counsel patients on weight management? 107 (97.3%) 50 (100%) 0.238 
Do you counsel patients on healthy eating habits? 100 (90.9%) 48 (96.0%) 0.257 
Do you counsel patients on physical activity? 106 (96.4%) 50 (100%) 0.172 
Do you counsel patients on smoking cessation? 108 (98.2%) 50 (100%) 0.337 
Do you counsel type 2 diabetes patients on weight management? 107 (97.3%) 48 (96.0%) 0.668 
Do you counsel type 2 diabetes patients on healthy eating habits? 102 (92.7%) 49 (98.0%) 0.180 
Do you counsel type 2 diabetes patients on physical activity? 108 (98.2%) 50 (100%) 0.337 
Do you counsel type 2 diabetes patients on smoking cessation? 107 (97.3%) 50 (100%) 0.668 
*p<0.05 
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Table 4.5: Sex Differences in Family Physician Attitudes Toward Diabetes 
 
 
 n (%)  Always/ Often  
Male Physicians 
(n=110) 
Female Physicians 
(n=51) 
p-value 
How often do you use the 2008 Canadian Diabetes Association’s 
Clinical Practice Guidelines as a decision support tool? 
90 (82.6%) 42 (85.7%) 0.622 
How often do you screen high-risk patients for type 2 diabetes? 106 (98.1%) 49 (98.0%) 0.949 
How often do you refer your patients to a registered dietician? 81 (74.3%) 32 (64.0%) 0.183 
How often do you refer your type 2 diabetes patients to a 
registered dietician? 
103 (94.5%) 48 (96.0%) 0.687 
 n (%)  Agree  
According to the 2008 CDA’s Clinical Practice Guidelines, 
screening for type 2 diabetes should be performed every 3 years 
among individuals > 40 years of age with no other risk factors? 
75 (71.4%) 37 (78.7%) 0.345 
Screening all high-risk patients for type 2 diabetes is feasible in a 
day-to-day medical practice. 
98 (92.5%) 46 (92.0%) 0.921 
Tight blood glucose control for patients with type 2 diabetes will 
reduce complications for the patient in the long term. 
92 (87.6%) 41 (89.1%) 0.792 
Early treatment of patients with impaired fasting glucose (IFG) 
will reduce complications in the long term? 
99 (92.5%) 47 (95.9%) 0.422 
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4.5 Discussion 
 
 The results of this study found that only 5.4% of family physicians reported that none of 
their patients had complications at the time of diagnosis. Most family physicians in this province 
have patients with complications present when they are diagnosed with diabetes. This suggests a 
late diagnosis since hyperglycemia can be present for many years
1
 and studies have shown that 
type 2 diabetes can be present for up to 12 years before being clinically diagnosed
2, 3
. In addition, 
symptoms of diabetes are often not present or develop slowly and may not be noticed for years. 
Symptoms such as fatigue, frequent urination and excessive thirst are often ignored or can often 
be attributed to less serious conditions. Singh et al.
4
 found that 40% of patients with diabetes had 
symptoms for more than 12 months prior to being diagnosed. Patients can often put off seeing 
their doctor, especially if they do not recognize the symptoms of diabetes and if they are not 
feeling ill. According to Koopman et al.
5
, patients often attribute diabetes symptoms to other 
causes and are often not aware that these symptoms are related to diabetes. Also, patients have 
limited knowledge of diabetes symptoms prior to being diagnosed, even when they had close 
family members with diabetes.
  
 
However, it is not only knowledge of symptoms that can affect when a person is 
diagnosed but understanding that diabetes is a serious condition
15
. Murphy & Kinmonth
16
 found 
that people with diabetes interpreted the disease in terms of avoiding short term symptoms or 
avoiding long term complications. Those who focused on the complications rather than the 
symptoms tended to believe that diabetes was a serious condition. However, those who did not 
have symptoms did not think diabetes was serious and described themselves as having a mild 
form of diabetes. Similarly, a study by Dietrich
17
 found that patients who did not feel sick do not 
take their diabetes diagnosis serious. However, this can change once they are prescribed insulin 
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or develop complications. Also, patients who are diagnosed with prediabetes do not take this 
seriously as they often do not consider this ‘real’ diabetes and as a result do not adopt the proper 
risk reduction behaviours
18
. Educating individuals on the seriousness of diabetes could 
potentially result in early diagnosis and prevent the progression to complications. It is essential 
that family physicians encourage risk reduction behaviours.
 
Previous research has found that primary care provider attitudes about diabetes impact 
how patients view the disease
19
. The reaction and attitude of physicians at the time of diagnosis 
are important factors that influence the perceived seriousness of the disease and the patients’ 
compliance to treatment
17
. Physician attitudes toward diabetes management may be more 
important than knowledge of the disease
20
. This is encouraging since family physicians in this 
province have positive attitudes toward diabetes management. This study found that the majority 
of family physicians refer type 2 diabetes patients to a registered dietician and feel that screening 
high-risk patients is feasible in a day-to-day medical practice. Also, the majority of family 
physicians report counselling patients and patients with type 2 diabetes on weight management, 
healthy eating habits, physical activity and smoking cessation. This is important since previous 
research has found that physician advice is associated with the reported adoption of healthy 
behaviours such as weight loss, physical activity, healthy eating and smoking cessation
18, 21-22
. 
While the majority of family physicians report they screen high-risk patients for type 2 
diabetes not all agreed that individuals aged 40 years and older with no risk factors should be 
screened for type 2 diabetes every three years, which is recommended by the Canadian Diabetes 
Association’s Clinical Practice Guidelines. When asked, the majority of family physicians said 
they use the 2008 Canadian Diabetes Association’s (CDA) Clinical Practice Guidelines (CPG) as 
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a decision support tool. These evidence-based recommendations are published every five years 
to guide healthcare professionals in the prevention and management of diabetes in Canada
23
. 
Worrall et al.
24
 evaluated family physician compliance with the CDA’s guidelines in 
Newfoundland and Labrador and found that CPGs were generally not being followed. Adherence 
to some guidelines was very good while adherence to others were poor. All patients had their 
blood pressure checked and 83% had their weight measured at visits. This study also found that 
the majority of family physicians checked their patient’s blood pressure at every visit; however 
only 31.3% of family physicians recorded their patient’s weight at every visit. Since the majority 
of individuals with diabetes are overweight or obese, the CDA’s CPGs recommend interventions 
in overweight and obese individuals with diabetes or those at risk for diabetes in an effort to 
prevent weight gain and to achieve and maintain a reduced body weight
23
. Research has shown 
that even losing 5% to 10% of initial body weight can improve glycemic control and 
cardiovascular disease risk factors
8, 9
. 
We found that male and female family physicians were similar in their diagnosis, 
treatment and management practices and in their attitudes toward diabetes. This finding is 
different from previous research which has found that female physicians are more likely to 
provide preventive services and counselling than male physicians
25-27
. Also, previous research 
findings suggest that female physicians may provide better quality of diabetes care than male 
physicians
28
. However, this study did find that male family physicians were more likely than 
female family physicians to agree that HbA1C is useful for screening (32.7% versus 16.0%, 
p<0.05) and male family physicians use HbA1C as a screening method more than female family 
physicians (45.9% versus 23.5%, p<0.05). This difference is not overly concerning since the 
2013 CDA’s CPGs allow for the diagnosis of diabetes to be made on the basis of either a fasting 
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plasma glucose test, HbA1C, 2-hour plasma glucose in a 75 gram oral glucose tolerance test or a 
random plasma glucose test. The decision of which test to use to diagnose diabetes is left to the 
discretion of the physician
23
. 
 
4.5.1 Limitations 
The following limitations should be considered when interpreting the results of this 
study. A response rate of 33.3% is not high; however, this is not surprising for the physician 
population, given the demands on their time. Previous studies have also reported low response 
rates in mailed surveys to family physicians
29, 30
 and it has been suggested that response rates are 
declining
29
. In 2009, when this survey was conducted, 30.7% of practicing physicians in NL 
were female and 69.3% were male
31
. This is comparable to the males and females who 
responded to our survey (31.7% female versus 68.3% male). Similarly, in 2009, 59.8% of 
practicing physicians in NL were paid on a fee-for-service schedule and 37.1% were salaried. 
This is also comparable to our study in which 64% of family physicians responding to the survey 
were fee-for-service family physicians and 32.9% were salaried
30
. Nevertheless, the results of 
this study may not reflect the opinions of family physicians who did not respond.  
In addition, item non-response occurred in this survey as certain questions were not 
answered by all respondents. This is unlikely to have impacted the results in a major way as the 
large majority of respondents did answer most questions. Also, response bias could have affected 
the results as this study depended on physicians self reporting how they manage and treat their 
patients. Recall bias could also have affected the results since physicians would have to recall 
how many diabetes patients they have and what their status was at the time of diagnosis.  
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At the time this study was conducted the 2008 Canadian Diabetes Association clinical 
practice guidelines were the most recent guidelines. There are some notable differences between 
the 2008 guidelines and the most current guidelines. In 2013, the Canadian Diabetes Association 
released the 2013 clinical practice guidelines. The 2008 version did not recommend using 
HbA1C as a screening test
23
; however, the 2013 version has including HbA1C as a screening test 
in addition to FPG, casual plasma glucose and the 2 hour plasma glucose in 75 g OGTT. The 
2013 Canadian Diabetes Association clinical practice guidelines recommend routine screening 
be performed every 3 years in individuals 40 years of age and older or those considered to be at 
high risk
32
. In contrast, in 2012 the Canadian Task Force on Preventive Health Care recommends 
not routinely screening adults at low to moderate risk. It recommends routine screening for 
adults at high risk every 3-5 years and recommends annual screening for adults at very high 
risk
33
. Both the Canadian Diabetes Association clinical practice guidelines and the Canadian 
Task Force on Preventive Health Care recommend an HbA1C value of 6.5% or greater as the 
threshold for diagnosing diabetes. Also, both leave the decision of which test to use to diagnose 
diabetes to the discretion of the physician and suggest that an abnormal level may require repeat 
testing to confirm a diagnosis of diabetes
32, 33
.  
 
4.6 Conclusion 
In conclusion, the results of this study show that the majority of family physicians in this 
province have patients with complications present when they are diagnosed with diabetes. 
Family physicians have positive attitudes toward diabetes management; however, patient’s body 
weights are not monitored to the extent blood pressure is. Male and female family physicians 
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were similar in their diagnosis, treatment and management practices and in their attitudes toward 
diabetes. 
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CHAPTER 5  General Discussion and Summary 
 
 
 
5.1 Summary of Key Findings 
This thesis examined diabetes and early and late diagnosis of diabetes in the province of 
Newfoundland and Labrador. A review of the literature revealed that type 2 diabetes can be 
present for a long period of time before being diagnosed. Insulin resistance and beta-cell 
dysfunction are largely responsible for the development of diabetes and its related complications 
and both are present very early in the natural history of the disease
1
. Hyperglycemia may be 
present for more than 20 years
2
 and type 2 diabetes can be present for up to 12 years before 
being diagnosed
3, 4
. As a result newly diagnosed patients can have complications at the time of 
diagnosis. It has been estimated that 2-39% of newly diagnosed patients have retinopathy, 8-18% 
have nephropathy, 5-13% have neuropathy and 8% have cardiovascular disease
5
. On average a 
person has diabetes for about 5 or 6 years before complications develop
6
. Randomized control 
trials have shown that diet and exercise can prevent or delay the progression from impaired 
glucose tolerance to diabetes
7, 8
. Intensive lifestyle interventions have been found to be more 
effective than metformin
9
 and intensive blood glucose control has been shown to reduce diabetes 
related microvascular complications
10, 11
. 
The objectives of this thesis were to use administrative data to develop a case definition 
of early and late diabetes diagnosis based on when comorbidities or complications develop; 
describe what factors are associated with a diabetes diagnosis and a late diabetes diagnosis, for 
males and females; mortality and hospitalization outcomes for males and females with diabetes 
and those diagnosed early and late; and, to describe how male and female family physicians 
diagnose, treat, and manage type 2 diabetes. After developing a series of definitions ranging 
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from specific to very broad (6 months to 2 years, before/after diagnosis) sample sizes were 
determined and assessed. Since there was little change in the sample distribution across 
definitions, the range of 6 months before and after diagnosis was used to define early and late 
diabetes diagnosis. Administrative data were used to identify individuals diagnosed early and 
late with diabetes. The Canadian Chronic Diseases Surveillance System (CCDSS) was used to 
identify records for those with diabetes. These records were linked to the Medical Care Plan 
(MCP) Fee-For-Service Physician Claims Database and the Clinical Database Management 
System (CDMS) data. Those data were used to determine when hospital and physician visits for 
diabetes related comorbidities or complications occurred and these were compared to the 
diabetes case dates. Incident diabetes patients without any diabetes related comorbidities or 
complications within 6 months before or after the diabetes case date were classified as being 
early diagnosed while those with a late diagnosis were defined as incident diabetes patients with 
at least one diabetes related comorbidity or complication within 6 months before or after 
diagnosis. 
In chapter 2 factors associated with a diabetes diagnosis and late diabetes diagnosis for 
males and females were examined. The results of this study suggest that different factors are 
associated with diabetes for males and females. For males, overweight/obesity was positively 
associated with diabetes while being a regular/occasional drinker was inversely associated with 
diabetes. Living in a rural area, receiving social assistance, having poor self perceived health, 
and considering most days stressful were positively associated with diabetes for females. The 
factors associated with a late diabetes diagnosis were also different for males and females. While 
no factors were significantly associated with a late diabetes diagnosis for males, having a low 
education was inversely associated with a late diabetes diagnosis for females. 
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In chapter 3 all-cause and cardiovascular mortality and hospitalizations for males and 
females with and without diabetes and those diagnosed early and late with diabetes were 
assessed. After adjusting for covariates, not only was diabetes positively associated with all-
cause mortality and CVD hospitalizations for females, the risk was significantly higher 
compared to their male counterparts. After adjusting for covariates, an early diagnosis does not 
appear to have an impact on all-cause, CVD, AMI or stroke mortality. However, the 
hospitalization results suggest that an early diagnosis does increase the risk of all-cause, CVD, 
and AMI hospitalizations compared to individuals without diabetes. Males and females 
diagnosed late with diabetes had an increased risk of all-cause mortality, CVD mortality and 
CVD hospitalizations compared to those without diabetes. The risk of CVD mortality and 
hospitalizations for females diagnosed late compared to females without diabetes was 
significantly higher when compared to their male counterparts. While diabetes increases the risk 
of mortality and hospitalizations for both males and females, females appear to be at a higher 
risk than males. Our results suggested that CVD, in particular, had a greater impact on females 
with diabetes than males, especially when diabetes was diagnosed late.  
How family physicians diagnose, treat and manage type 2 diabetes was assessed in 
chapter 4. A secondary objective was to identify if there were any differences in how male and 
female family physicians diagnose, treat and manage those with type 2 diabetes. The results of 
this study suggested that the majority of family physicians in this province have patients with 
complications when they are diagnosed with diabetes. Family physicians have positive attitudes 
toward diabetes management; however, patient’s body weights are not monitored to the extent 
that blood pressure is. Male and female family physicians participating in the survey were 
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similar in their diagnosis, treatment and management practices and in their attitudes toward 
diabetes. 
 
5.2 Recommendations for Future Research 
5.2.1 Definition of Early and Late Diabetes Diagnosis 
One of the objectives of this dissertation was to use administrative data to develop a case 
definition of early and late diabetes diagnosis based on when comorbidities or complications 
develop. A series of definitions ranging from specific to very broad (6 months to 2 years, 
before/after diagnosis) and sample sizes for each definition were developed. Since there was 
little change in the sample distribution across definitions, the range of 6 months before and after 
diagnosis was used to define early and late diabetes diagnosis. In addition, an internal medicine 
physician was consulted and agreed that the definition of 6 months before and after diagnosis 
was reasonable. Incident diabetes patients without any diabetes related comorbidities or 
complications within 6 months before or after the diabetes case date were classified as early 
diagnosed while those with a late diagnosis were defined as incident diabetes patients with at 
least one diabetes related comorbidity or complication within 6 months before or after diagnosis. 
Future research should aim to validate this definition of early and late diabetes diagnosis. 
Since many definitions of early and late diabetes diagnosis were tested and there was little 
change in the sample distribution across definitions, we feel that the range of 6 months before or 
after diagnosis is a good definition of early and late diabetes diagnosis. In an effort to capture all 
late diagnosed cases of diabetes, a broad range of comorbidities and complications were included 
in the case definition. The date an individual is identified as having diabetes in the CCDSS is not 
the date that diabetes developed. Type 2 diabetes can be present for up to 12 years before being 
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diagnosed
3, 4 
and on average an individual has diabetes for about 5 or 6 years before 
complications develop
6
. Since administrative data was used to identify diabetes cases, it was not 
possible to identify what is a comorbidity and what is a complication of diabetes since it is not 
possible to determine when diabetes developed, only when it was diagnosed. As a result, all 
possible comorbidities and complications of diabetes were included in the definition of early and 
late diagnosis. Also, the list of conditions used in the early and late case definition is extensive. 
Many of these conditions could have been due to conditions other than diabetes. For example, it 
is possible that for conditions such as renal disease, amyloidosis, hyperlipidemia, optic nerve 
problems, polyneuropathies, facial nerve disorders, inflammatory polyneuropathy, radiculopathy, 
and a number of others may not be due to complications of diabetes. Conditions such as 
hypertension may also be present prior to the onset of diabetes. In Chapter 2, for the CCHS 
cohort, hypertension was the condition that defined a late diagnosis in 30.4% of cases. In Chapter 
3, for the CCDSS cohort, hypertension was the condition that defined a late diagnosis in 71.1% 
of cases. Some misclassification is possible and therefore, it would be useful to test the case 
definition of early and late diabetes diagnosis using fewer comorbidities and complications. In 
addition, more research into when comorbidities and complications of diabetes develop is 
needed. 
Administrative data were used to identify individuals with diabetes and to identify those 
diagnosed early and late. The CCDSS diabetes case definition does not differentiate between 
type 1 and type 2 diabetes. However, since most adults are diagnosed with type 2 diabetes
12
, it is 
unlikely to have a major impact on the results. Furthermore, the CCDSS diabetes case definition 
uses the Medical Care Plan (MCP) Fee-For-Service Physician Claims Database. MCP data was 
also used in the definition of early and late diabetes diagnosis. Records for those with diabetes 
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were linked to the MCP and CDMS data to identify when hospital and physician visits for 
diabetes related comorbidities or complications occurred and these were compared to the 
diabetes case dates. In Newfoundland and Labrador, one-third of the province’s physicians are 
paid on a salary basis and these physicians are not required to submit medical claims so 
information on these visits is not captured. Some misclassification could have occurred as 
individuals with diabetes could have been classified as not having diabetes or classified as early 
or late diagnosed because a salaried physician provided most of their care. Also, the definition of 
early and late depends on conditions identified through healthcare services covered by MCP. 
Conditions identified through healthcare services not covered by MCP could not be captured. 
Optometry services are not covered under MCP, therefore retinopathy would not be captured 
unless it was included in the CDMS data. Using medical charts instead of the MCP data would 
be a richer and more complete data source. However, the time required to review medical charts 
would be extensive. Once a provincial electronic medical record is developed and being used by 
all physicians in the province, the EMR data could then be used to validate the early and late 
diagnosis definition.  
 
5.2.2 Factors Associated with a Diabetes Diagnosis and Late Diabetes Diagnosis for Males 
and Females 
 
This study found that different factors are associated with the occurrence of diabetes in 
males and females. For males, lifestyle factors such as BMI and alcohol consumption impact 
whether or not they will be diagnosed with diabetes. Njolstad et al.
13
 also found that BMI was 
positively associated with diabetes and, after controlling for other factors, BMI was a stronger 
predictor in men. Since men are diagnosed at lower BMI levels than females, they may be more 
susceptible to diabetes than females
14
. In addition, males usually carry weight in their abdominal 
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region and females tend to carry weight in their hips and thighs
15
. It has been suggested that 
abdominal fat is associated with higher risk of diabetes and this could explain the greater risk of 
diabetes in overweight and obese men compared to women. Similarly, Rasouli et al.
16
 found that 
moderate alcohol consumption is protective for type 2 diabetes in males but not in females. The 
authors suggest that females could be more sensitive to the negative effects of alcohol compared 
to males or that females are more likely than males to underreport their alcohol intake. 
This study found that for females, disadvantages such as living in a rural area, receiving 
social assistance, having poor self perceived health, and considering most days stressful were 
positively associated with diabetes. Previous research has also found that diabetes risk is higher 
for lower income groups compared to higher income groups and the risk was higher for lower 
income females compared to males
17, 18
. 
Females with diabetes report having a worse health situation than males and are more 
likely to rate their health as poor compared to males
19
. In addition, females are less likely to rate 
their health as excellent compared with males
20
. One explanation for the discrepancy is that men 
and women use different information when making assessments about their health. Women have 
been found to base their health ratings on both serious and mild diseases, while men base them 
on serious illness only
21
.  
Previous research has also found that stress increases the risk of diabetes
22, 23
. One 
explanation for this finding is that stress is also associated with unhealthy lifestyle behaviors, 
such as unhealthy eating, physical inactivity, smoking, and alcohol abuse. These factors are also 
risk factors for developing diabetes
24, 25
. 
This study also found that the factors associated with a late diabetes diagnosis were 
different for males and females. While no factors were significantly associated with a late 
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diabetes diagnosis for males, having a low education was inversely associated with a late 
diabetes diagnosis for females. Most research suggests that individuals with low levels of 
education have a higher risk of diabetes and that the association is stronger in females
26-28
. 
However, Chien et al.
29
 found that higher education levels were significantly associated with 
developing pre-diabetes or type 2 diabetes and this finding was significant for females only. 
More research is needed on why males and females develop diabetes, when they are diagnosed, 
and why females are at greater risk than males.  
 
5.2.3 Sex Differences in All-Cause and Cardiovascular Mortality and Hospitalization for 
Individuals With and Without Diabetes and Patients Diagnosed Early and Late With 
Diabetes 
 
This study found that diabetes was positively associated with all-cause mortality and 
CVD hospitalizations for females and the risk was significantly higher compared to their male 
counterparts. Males and females diagnosed late with diabetes had an increased risk of all-cause 
mortality, CVD mortality and CVD hospitalizations compared to those without diabetes. The risk 
of CVD mortality and hospitalizations for females diagnosed late compared to females without 
diabetes was significantly higher when compared to their male counterparts. While diabetes 
increased the risk of mortality and hospitalizations for both males and females, females had a 
higher risk than males. CVD, in particular, had a greater impact on females with diabetes than 
males, especially when diabetes was diagnosed late.  
Previous studies have also found that individuals with diabetes have an increased risk of 
mortality and morbidity related to all-causes, CVD, AMI, and stroke compared to individuals 
without diabetes
30-33
. In addition, previous studies also found that females with diabetes are at a 
greater risk of mortality and morbidity than males with diabetes
30, 31, 33-38
. It is not known why 
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females with diabetes had an increased risk of mortality and hospitalizations compared to males 
with diabetes. One explanation is that CVD risk factors have a stronger impact on females than 
males
39-42
. Another possible explanation is that CVD risk factors are less aggressively treated in 
females
43-45
. More research is needed to determine why females had a greater risk of adverse 
outcomes compared to males.  
In terms of diabetes management the same HbA1C target and treatment plan should not 
be applied to all patients with diabetes. Perhaps the focus should not only be on glucose control 
but on all CVD risk factors. The Canadian Diabetes Association Clinical Practice Guidelines 
provide recommended targets for glycemic control and suggest that treatment strategies should 
be individualized with consideration given to presence of risk factors
46
. Early and aggressive 
treatment had been suggested for newly diagnosed patients without a history of CVD while less 
aggressive treatment may be suitable for older patients who have had diabetes for a longer period 
of time and who have a history of CVD
47
. However, this recommendation does not take into 
account the greater CVD risk that females with diabetes have. More research into whether 
different treatment plans based on sex and timing of diabetes diagnosis would be beneficial is 
needed.  
 
5.2.4 Diabetes Diagnosis and Late Diabetes Diagnosis from the Family Physician 
Perspective 
 
The results of this study suggest that the majority of family physicians in this province 
have patients with complications present when they are diagnosed with diabetes. Family 
physicians have positive attitudes toward diabetes management; however, patient’s body weights 
are not monitored to the extent blood pressure is. Previous research in Newfoundland and 
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Labrador found that adherence to clinical practice guidelines such as blood pressure monitoring 
and weight measurement was very good
48
. 
This study also found that male and female family physicians were similar in their 
diagnosis, treatment, management practices, and in their attitudes toward diabetes. This finding 
is different from previous research which has found that female family physicians are more 
likely to provide preventive services and counselling than male family physicians
49-51
 and may 
provide better quality of diabetes care than male physicians
52
. 
Since this study relied on family physicians’ self reporting, response bias and recall bias 
would have impacted the results. Future research using medical charts to determine how family 
physicians diagnose, treat and manage diabetes would provide more accurate results. In addition, 
once a provincial electronic medical record is developed and being used by all physicians in the 
province, this data could also be used to assess physician practices. Future studies should also 
focus on management strategies for dealing with diabetes complications such as foot 
examinations and referrals for eye exams. 
 
5.3 Conclusions 
In conclusion, certain risk factors appear to impact males and females differently and 
more research is needed on how males and females develop diabetes and timing of diagnosis. 
Different management strategies could be considered for males and females and those diagnosed 
early and late with diabetes. Also, family physicians need to monitor all risk factors for diabetes 
complications closely in an attempt to better manage progression of the disease.  
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Appendix A 
 
Conditions used to Identify Early and Late Diabetes Diagnoses 
 
Conditions ICD 9 Codes ICD-10-CA Codes 
Cardiovascular Disease  390-448 I00-I78 
Ischemic Heart Disease  410-414 I20-I25 
Hypertensive Disease  I10-I13, I15 
Acute Myocardial Infarction  410 I21-I22 
Heart Failure  428 I50 
Stroke 430-438 I60-I69 
Renal Disease  585-586 N18-N19 
Atherosclerosis 440  
Amyloidosis  277.3 E85 
Other peripheral vascular diseases 443 I73 
Other and unspecified hyperlipidaemia  372.4  
Other proliferative retinopathy: poliferative vitreo-retinopathy   H35.2 
Chorioretinal scars  363 H31.0 
Atherosclerotic retinopathy  I70.8 H36.8 
Other disorders of optic nerve and visual pathways  H47 
Other retinal disorders  362 H35 
Nephritis and nephropathy, not specified as acute or chronic  583  
Acute renal failure 584  
Disorder of kidney and ureter, unspecified  N28.9 
Other renal tubulo-interstitial diseases   N15 
Acute nephritic syndrome  N00 
Unspecified nephritic syndrome   N05 
Isolated proteinuria with specified morphological lesion   N06 
Neuromuscular dysfunction of bladder, not elsewhere classified   N31 
Other polyneuropathies   G62 
Nerve root and plexus disorders 353 G54 
Other mononeuropathies    G58 
Mononeuropathies of lower limb   G57 
Mononeuropathies of upper limb   G56 
Facial nerve disorders  351 G51 
Disorders of autonomic nervous system  337 G90 
Inflammatory polyneuropathy  G61 
Radiculopathy  M54 
Mononeuritis of upper limb and mononeuritis multiplex  354  
Mononeuritis of lower limb  355  
Neuralgia, neuritis, and radiculitis, unspecified 729.2  
Lower Limb amputations  
 
96.11, 96.12, 
96.13, 96.14, 
96.15, 96.2 
1VC93LA, 
1VG93LA, 
1VQ93LA, 
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1WA93LA, 
1WE93LA, 
1WJ93LA, 
1WL93LA, 
1WM93LA, 
1WV59LA 
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237 did not give permission to link;  
759 < age 25 when interviewed  
 
 
CCHS 2000/01 share file 
3,734 records 
CCHS 2003 share file 
3,802 records 
CCHS 2005 share file 
3,956 records 
CCHS 2000/01 
2,481 records 
 
CCHS 2003 
2,193 records 
CCHS 2005 
2,495 records 
CCHS Combined File 
7,169 records 
Final CCHS File 
7,101 records 
68 duplicates 
Final File CCHS file linked to  
CDMS and MCP to identify those diagnosed early and late with 
diabetes 
397 did not give permission to link; 
706 < age 25 when interviewed  
 
 
267 did not give permission to link; 
674 < age 25 when interviewed  
 
 
link to MCP master file  
 
2003 share file linked to link file  
 2,699 records  
link to CCDSS  
2,307 records 
 
392 records without MCP # 
114 non incident cases;  118 non incident cases;  
2000/01 share file linked to link file  
 2,738 records  
92 non incident cases;  
link to MCP master file  
 
link to MCP master file  
 
link to CCDSS  
2,599 records 
 
link to CCDSS  
2,587 records 
 
2005 share file linked to link file  
 3,015 records  
139 records without MCP # 428 records without MCP # 
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Letter of Information  
 
Title of Research Project: Assessing Determinants of Early versus Late Diagnosis of Type 2-
Diabetes from the Patient, Physician and Policy/Decision Maker Perspective in Newfoundland 
and Labrador 
 
Investigators: Kayla Collins, MSc, PhD(c), Madonna Murphy, MSc, PhD(c), Don MacDonald, 
MSc, PhD, Reza Alaghehbandan, MD 
 
 
You have been invited to take part in a research study.  It is up to you to decide whether to be in 
the study or not.  Before you decide, you need to understand what the study is for, what risks you 
might take and what benefits you might receive.  This letter of information explains the study.   
 
The researchers will: 
 discuss the study with you 
 answer your questions 
 keep confidential any information which could identify you personally 
 be available during the study to deal with problems and answer questions 
 
Introduction/Background 
Diabetes is a serious chronic disease associated with multiple complications and premature 
death.  A challenge with type 2-diabetes has always been the late diagnosis of the disease. It has 
been proven that type 2-diabetes can be prevented or delayed through lifestyle modifications 
among those at high risk of developing the disease. Early detection and management is important 
for good control of diabetes and to prevent late complications. 
 
Purpose of the Research 
The purpose of this study is to examine the reasons why some people are diagnosed with 
diabetes early when they first develop the condition, while other people are diagnosed later after 
they have had the condition for some time. We are examining this from three perspectives, 
including the patient, physician and policy/decision maker perspective. The findings of this study 
will be used to support public health decision-making for diabetes prevention and management.  
 
Description of the Study Procedures 
Your role in this research will involve completing and returning the enclosed survey. All of the 
work on this study will be carried out at the Newfoundland and Labrador Centre for Health 
Information.  
 
Length of Time 
It is estimated that it will take 10 minutes of your time to complete the enclosed survey. 
 
Possible Risks or Discomforts 
There are no anticipated risks or discomforts associated with your participation in this study 
except for the time taken to complete the survey.  
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Possible Benefits 
You will not personally receive any benefit from participating, however, the information we will 
collect may help us find ways to improve care for people with diabetes. 
Liability Statement 
Completing and returning this survey gives us your implied consent to be in this study.  It tells us 
that you understand the information about the research study and that you understand you are 
returning the survey anonymously. Since this survey will be returned anonymously there is no 
risk of identifying a clinic or a physician. Researchers or agencies involved in this research study 
still have their legal and professional responsibilities. Throughout the study, all data will be 
securely stored at the Newfoundland and Labrador Centre for Health Information in locked filing 
cabinets and password protected computer files.   
 
Distribution of Research Findings 
A final report describing the overall findings from this study will be submitted to the provincial 
Department of Health and Community Services, the Public Health Agency of Canada and sent to 
health professionals with an interest in this research.  The findings of the study will be submitted 
for publication in academic journals and presented at health/scientific conferences.  Any report 
produced from the study will also be made available electronically, free of charge, on the 
Centre’s website (www.nlchi.nl.ca). If you would like a hard copy of the study summary, please 
contact the Principal Investigator (contact information below). 
 
Questions 
If you have any questions about taking part in this study, or need any additional information, 
please contact: 
 
Kayla Collins,  
Director, Research and Evaluation  
Newfoundland and Labrador Centre for Health Information  
(709) 752-6045  
email: kayla.collins@nlchi.nl.ca 
 
Madonna Murphy,  
Manager, Research  
Newfoundland and Labrador Centre for Health Information  
(709) 752-6037  
email: donna.murphy@nlchi.nl.ca 
 
Or you can talk to someone who is not involved with the study at all, but can advise you on your 
rights as a participant in a research study.  This person can be reached through: 
 
Office of the Human Investigation Committee (HIC)  
(709) 777-6974            
email: hic@mun.ca 
 
 
This is your copy of the Letter of Information to keep for your records 
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Physician Survey 
 
Assessing Determinants of Early versus Late Diagnosis of Type 2-Diabetes from the Patient, 
Physician and Policy/Decision Maker Perspective in Newfoundland and Labrador 
 
 
 
1. Do you provide care (screening and/or treatment) to patients with type 2-diabetes? 
  Yes    No  
2. Is your practice involved in the Chronic Disease Management Diabetes Collaborative? 
  Yes    No  
 
3. Approximately what percentage of your current patients have been diagnosed with type 2-   
   diabetes? 
 
                              % 
4. Approximately what percentage of your current type 2-diabetes patients have diabetes related   
   complications at the time of diagnosis? 
 
                              % 
5. What percentage of your patients with type 2-diabetes are required to receive care from a   
     specialist? 
 
                                %   Not Applicable 
 
6. How often do you use the 2008 Canadian Diabetes Association’s Clinical Practice Guidelines  
    as a decision support tool? 
 Always   Seldom  
 Often   Never   
 
7. How often do you screen high-risk patients for type 2-diabetes? 
 Always   Seldom   Not Applicable  
  Often   Never  
 
8. Which screening method(s) do you use (Check all that apply)? 
 Fasting plasma glucose (FPG)   
 Casual plasma glucose (PG)   
  2-hours plasma glucose (2hPG) in a 75-g oral glucose tolerance test (OGTT)   
  Glycosylated haemoglobin (A1c) 
  None of the above 
  Other 
 
9. At what fasting plasma glucose (FPG) level do you usually make a diagnosis of type 2-diabetes? 
 
 
 
Items 1-17 relate to diagnosis and treatment of type 2-diabetes. 
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10. At what FPG level do you usually initiate a nonpharmacologic (i.e. lifestyle) treatment? 
 
11. At what FPG level do you usually initiate a pharmacologic treatment? 
 
 
12. Measuring Glycosylated haemoglobin (A1c) is useful for (Check all that apply): 
 Screening    Treatment   Blood glucose monitoring  
 
13. Do you recommend home glucose monitoring to your type 2-diabetes patients? 
 Yes     No 
 
14. For patients with type 2-diabetes, do you record their weight at every visit? 
 Yes     No 
 
15. For patients with type 2-diabetes, do you check their blood pressure at every visit? 
 Yes    No 
 
16. a. How often do you refer your patients to a registered dietician (where applicable)? 
 Always   Seldom   Often   Never  
       
      b. How often do you refer your type 2-diabetes patients to a registered dietician? 
   Always   Seldom   Often   Never  
17. a. Where applicable, do you counsel your patients on the following topics? 
          (Check all that apply) 
 Weight management   Physical activity  Smoking cessation   
Healthy eating habits   None of the above   
 Other 
    
      b. Do you counsel your type 2-diabetes patients on the following topics?          
          (Check all that apply) 
 Weight management   Physical activity  Smoking cessation   
Healthy eating habits   None of the above   
 Other 
 
 
 
18. According to the 2008 CDA’s Clinical Practice Guidelines, screening for type 2-diabetes should    
      be performed every 3 years among individuals > 40 years of age with no other risk factors. 
 Strongly disagree   
 Somewhat disagree   
  Neither agree nor disagree   
  Somewhat agree 
  Strongly agree 
 
For items 18-21please indicate the extent to which you agree/disagree with the following statements. 
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19. Screening all high-risk patients for type 2-diabetes is feasible in a day-to-day medical practice. 
 Strongly disagree   
 Somewhat disagree   
  Neither agree nor disagree   
  Somewhat agree 
  Strongly agree 
20. Tight blood glucose control for patients with type 2-diabetes will reduce complications for the  
      patient in the long term. 
 Strongly disagree   
 Somewhat disagree   
  Neither agree nor disagree   
  Somewhat agree 
  Strongly agree 
21. Early treatment of patients with impaired fasting glucose (IFG) will reduce complications  
      in the long term. 
 Strongly disagree   
 Somewhat disagree   
  Neither agree nor disagree   
  Somewhat agree 
  Strongly agree 
 
 
 
22. Please indicate your sex: 
 Male   Female 
23. What is your month and year of birth?                          
       Month         Year 
24. How long have you been practicing as a physician?  
               years 
25. What is your specialty?  
26. Which of the following best describes the primary setting in which you practice? 
 Hospital/Health Centre  Group Practice 
  Private    Other (please specify)  
27. Which of the following best describes the area in which your practice is located? 
 Rural ( 5,000 inhabitants)           Urban (> 5,000 inhabitants) 
 
28. Which of the following best describes the billing structure of your practice? 
 Fee for Service       Salaried Community Based Physician 
  Salaried Academic Physician      Other (please specify)  
Thank you for volunteering your time to participate in this study. 
Items 22-28 are intended to help us group responses based on similar demographic characteristics. 
Please respond to only those items which you are comfortable with. 
 
